

**ShareHope Medicine Co., Ltd. and its  
subsidiaries**

**Consolidated Financial Statements and  
Independent Auditors' Review Report**

**For the Three Months Ended March 31, 2025 and 2024**

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China.

In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

**Address: 19th Floor, No. 168 Jingguo Road, Taoyuan District, Taoyuan**  
**Tel.:(03)3469595**

# Table of Contents

<b>Item</b>	<b>Page No.</b>
I.Cover	1
II.Table of Contents	2
III.Independent Auditors' Review Report	3
IV.Consolidated Balance Sheet	4
V.Consolidated Statement of Comprehensive Income	5
VI.Consolidated Statement of Changes in Equity	6
VII.Consolidated Cash Flow Statement	7
VIII.Notes to Consolidated Financial Statements	
(I) Company History	8
(II) Date and Procedure of the Approval of the Financial Statements	8
(III) Application of Newly Issued and Amended Standards and Interpretations	8~10
(IV) Summary of Major Accounting Policies	10~13
(V) Major Sources of Uncertainty in Major Accounting Judgments, Estimates and Assumptions	13
(VI) Explanation of Significant Accounting Items	14~50
(VII) Transactions of Related Parties	50~57
(VIII) Pledged Assets	57
(IX) Material Contingent Liabilities and Unrecognized Contractual Commitments	57~58
(X) Material Losses from Disasters	58
(XI) Material Subsequent Events	58
(XII) Others	58
(XIII) Items Disclosed in Notes	
1. Information on major transactions	58~62
2. Information on reinvestment	62~64
3. Information on investments in mainland China	64
(XIV) Department Information	65

## **Independent Auditors' Review Report**

Submitted to the Board of Directors of ShareHope Medicine Co., Ltd. and subsidiaries for review

### **Introduction**

The Consolidated Balance Sheet of ShareHope Medicine Co., Ltd. and its subsidiaries as of March 31, 2025 and 2024, and the Consolidated Statement of Comprehensive Income, Consolidated Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to Consolidated Financial Statements (including the Summary of Major Accounting Policies) for the three months ended March 31, 2025 and 2024, have been reviewed by the independent auditors. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

### **Scope of Review**

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying Consolidated Financial Statements do not present fairly, in all material respects, the consolidated financial position of ShareHope Medicine Co., Ltd. and its subsidiaries as of March 31, 2025 and 2024, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

KPMG Taiwan

Astor Kou

CPAs:

Sinney Kuo

Number of documents approved and  
certified by the securities regulatory: Tai-Cai-Zheng-Liu-Zi No. 0930106739  
Jin-Guan-Zheng-Shen-Zi No. 1040003949  
Date: May 9, 2025

## ShareHope Medicine Co., Ltd. and its subsidiaries

## Consolidated Balance Sheet

March 31, 2025, December 31 and March 31, 2024

Unit: NT\$ thousand

		2025.3.31		2024.12.31		2024.3.31				2025.3.31		2024.12.31		2024.3.31	
Assets		Amount	%	Amount	%	Amount	%	Liabilities and equity		Amount	%	Amount	%	Amount	%
<b>Current assets:</b>								<b>Current liabilities:</b>							
1100	Cash and cash equivalents (Note 6 (1))	\$ 1,530,503	22	1,459,635	20	1,261,724	17	2100	Short-term borrowings (Note 6(16) and 8)	\$ 446,268	7	433,087	6	367,007	5
1110	Financial assets at fair value through profit or loss - current (Note 6 (2))	10,650	-	10,610	-	10,497	-	2110	Short-term bills payable (Note 6(17))	34,947	-	54,815	1	54,994	1
1136	Financial assets at amortized cost - current (Note 8)	53,327	1	23,010	-	49,005	1	2130	Contract liabilities - current (Note 6 (26))	39,625	1	48,815	1	14,186	-
1150	Notes receivable (Note 6 (4) and (26))	8,696	-	11,320	-	10,945	-	2150	Notes payable	19,829	-	19,676	-	89,110	1
1170	Net accounts receivable (Note 6 (4) and (26))	267,611	4	258,074	4	276,637	4	2170	Accounts payable	607,272	9	664,386	9	706,570	9
1180	Net accounts receivable - related parties (Note 6 (4), (6) and (26), and Note 7)	949,298	14	971,225	14	1,041,628	14	2181	Accounts payable - related parties (Note 7)	988	-	1,020	-	2,926	-
1200	Other net accounts receivable (Note 6 (5))	30,546	1	50,829	1	65,903	1	2200	Other payables (Note 6(21))	186,591	3	251,605	4	211,621	3
1210	Other accounts receivable - related parties (Note 6 (5) and Note 7)	27,989	-	268,252	4	23,864	-	2220	Other accounts payable - related parties (Note 7)	1,908	-	26,746	-	1,909	-
1220	Income tax assets for the period	403	-	337	-	180	-	2230	Income tax liabilities for the period	35,635	1	24,433	-	63,304	1
130X	Inventories (Note 6 (7))	282,184	4	292,256	4	286,243	4	2260	Liabilities directly associated with disposal groups held for sale (Note (8))	-	-	-	-	43,176	1
1410	Prepayments (Note 7)	41,560	1	36,916	1	41,419	1	2280	Lease liabilities - current (Note 6(19))	104,611	2	109,778	2	115,511	2
1460	Disposal groups held for sale (Note 6(8))	-	-	-	-	56,043	1	2322	Long-term borrowings due within one year (Note 6(18) and 8)	99,649	1	185,158	2	115,947	2
1470	Other current assets	7,954	-	9,928	-	11,452	-	2323	Long-term accounts payable due in one year	-	-	-	-	2,769	-
<b>Total current assets</b>		3,210,721	47	3,392,392	48	3,135,540	43	2399	Other current liabilities	27,442	-	40,480	1	45,798	1
<b>Non-current assets:</b>								<b>Total current liabilities</b>		1,604,765	24	1,859,999	26	1,834,828	26
1510	Financial assets at fair value through profit or loss - non-current (Note 6 (2))	25,247	-	27,853	-	48,262	1	<b>Non-current liabilities:</b>							
1517	Financial assets at fair value through other comprehensive income - non-current (Note 6 (3))	720,106	11	770,686	11	898,224	12	2540	Long-term borrowings (Note 6(18) and 8)	878,462	13	825,235	12	991,940	13
1536	Financial assets at amortized cost - non-current (Note 8)	40,000	1	43,334	1	44,500	1	2570	Deferred income tax liabilities	19,495	-	29,198	1	46,587	1
1550	Equity method investments	75,027	1	76,056	1	77,041	1	2580	Lease liabilities - non-current (Note 6(19))	353,314	5	379,196	5	421,434	6
1600	Property, plant and equipment (Note 6(11) and 8)	1,495,657	22	1,490,229	21	1,642,802	22	2612	Long-term payables	-	-	-	-	7,739	-
1755	Right-of-use assets (Note 6(12))	333,222	5	350,060	5	371,073	5	2640	Net defined benefit liabilities - non-current	7,325	-	7,267	-	7,040	-
1760	Investment property (Note 6(13) and 8)	96,893	1	111,884	2	323,191	4	2645	Deposits received (Note 7)	17,676	-	19,756	-	18,803	-
1780	Intangible assets (Note 6(14))	318,230	5	322,120	4	333,904	5	<b>Total non-current liabilities</b>		1,276,272	18	1,260,652	18	1,493,543	20
1840	Deferred income tax assets	14,777	-	14,444	-	13,661	-	<b>Total liabilities</b>		2,881,037	42	3,120,651	44	3,328,371	46
194D	Net long-term finance lease receivables (Note 6 (6) and (26), and Note 7)	14,621	-	15,969	-	15,659	-	<b>Equity (Note 6(9), (10) and (24)):</b>							
1990	Other non-current assets (Note 6(15) and 7)	497,234	7	486,690	7	450,486	6	3110	Ordinary share capital	1,310,861	19	1,310,861	18	1,260,443	17
<b>Total non-current assets</b>		3,631,014	53	3,709,325	52	4,218,803	57	3200	Additional paid-in capital	1,150,037	17	1,150,037	16	1,153,697	16
<b>Total assets</b>		<b>\$ 6,841,735</b>	<b>100</b>	<b>7,101,717</b>	<b>100</b>	<b>7,354,343</b>	<b>100</b>	3310	Legal reserves	229,009	3	229,009	3	216,895	3
								3350	Undistributed earnings	851,019	13	819,984	12	756,639	10
								3410	Exchange difference from translation of the financial statements of foreign operations	(810)	-	(1,338)	-	(1,841)	-
								3420	Unrealized gains or losses on financial assets at fair value through other comprehensive income	10,808	-	48,342	1	177,747	2
									Total equity attributable to owners of the parent company	3,550,924	52	3,556,895	50	3,563,580	48
								36xx	Non-controlling interests	409,774	6	424,171	6	462,392	6
									<b>Total equity</b>	3,960,698	58	3,981,066	56	4,025,972	54
									<b>Total liabilities and equity</b>	<b>\$ 6,841,735</b>	<b>100</b>	<b>7,101,717</b>	<b>100</b>	<b>7,354,343</b>	<b>100</b>

(please refer to the attached Notes to the Consolidated Financial Report for details)

Chairman: Hung-Jen Yang

Manager: Ching-Wen Liu

Chief Accounting Officer: Ya-Mei Huang

**ShareHope Medicine Co., Ltd. and its subsidiaries**  
**Consolidated Statement of Comprehensive Income**  
**For the three months ended March 31, 2025 and 2024**

**Unit: NT\$ thousand**

		For the three months ended March 31, 2025		For the three months ended March 31, 2024	
		amount	%	amount	%
4000	<b>Operating revenue (Notes 6 (26) and 7)</b>	\$ 1,051,578	100	972,549	100
5000	<b>Operating costs (Notes 6(7), (11), (12), (22) and 7)</b>	(877,455)	(83)	(801,294)	(82)
	<b>Gross profit</b>	174,123	17	171,255	18
	<b>Operating expenses (Notes 6(4), (11), (12), (19), (22), and 7):</b>				
6100	Marketing expenses	(51,206)	(5)	(64,810)	(7)
6200	Administrative expenses	(107,650)	(11)	(102,185)	(11)
6300	R&D expenses	(2,006)	-	(2,088)	-
6235	Losses on expected credit impairment	(2,355)	-	(17)	-
	<b>Total operating expenses</b>	(163,217)	(16)	(169,100)	(18)
6500	Not other income and expenses (Notes 6(28) and 7)	19,603	2	20,658	2
	<b>Net operating income</b>	30,509	3	22,813	2
	<b>Non-operating income and expenses (Notes 6, (19) and (29)):</b>				
7100	Interest income	1,525	-	985	-
7010	Other income	12,427	1	8,298	1
7020	Other gains and losses	(2,230)	-	5,952	-
7050	Finance costs	(12,435)	(1)	(14,127)	(1)
7770	Share of (losses) gains of affiliates recognized by the equity method	(1,029)	-	463	-
	<b>Total non-operating income and expenses</b>	(1,742)	-	1,571	-
7900	<b>Net income before tax</b>	28,767	3	24,384	2
7950	<b>Income tax expenses (Note 6(23))</b>	(10,626)	(1)	(10,886)	(1)
	<b>Net income for the period</b>	18,141	2	13,498	1
8300	<b>Other comprehensive income (Notes 6(23) and (24)):</b>				
8310	<b>Items not reclassified to profit or loss</b>				
8316	Unrealized valuation profits and losses on equity instrument investments at fair value through other comprehensive income	(49,692)	(5)	66,612	7
8349	Less: income taxes related to non-reclassified items	(9,536)	(1)	13,250	1
	<b>Total items not reclassified to profit or loss</b>	(40,156)	(4)	53,362	6
8360	<b>Items that may be reclassified to profit or loss subsequently</b>				
8361	Exchange difference from translation of the financial statements of foreign operations	728	-	1,097	-
8399	Less: income taxes related to items that may be reclassified	129	-	206	-
	<b>Total items that may be reclassified to profit or loss subsequently</b>	599	-	891	-
8300	<b>Other comprehensive income for the period</b>	(39,557)	(4)	54,253	6
8500	<b>Total comprehensive income for this period</b>	<u>\$ (21,416)</u>	<u>(2)</u>	<u>67,751</u>	<u>7</u>
	<b>Net profit (loss) attributable to (Note 6(10)):</b>				
8610	Owners of the parent company	\$ 31,035	3	24,529	2
8620	Non-controlling interests	(12,894)	(1)	(11,031)	(1)
		<u>\$ 18,141</u>	<u>2</u>	<u>13,498</u>	<u>1</u>
	<b>Total comprehensive income attributable to (Note 6(10)):</b>				
8710	Owners of the parent company	\$ (5,971)	(1)	77,781	8
8720	Non-controlling interests	(15,445)	(1)	(10,030)	(1)
		<u>\$ (21,416)</u>	<u>(2)</u>	<u>67,751</u>	<u>7</u>
	<b>Earnings per share (NT\$) (Note 6(25))</b>				
9750	<b>Basic earnings per share</b>	<u>\$ 0.24</u>		<u>0.19</u>	
9850	<b>Diluted earnings per share</b>	<u>\$ 0.24</u>		<u>0.19</u>	

(please refer to the attached Notes to the Consolidated Financial Report for details)

Chairman: Hung-Jen Yang

Manager: Ching-Wen Liu

Chief Accounting Officer: Ya-Mei Huang

**ShareHope Medicine Co., Ltd. and its subsidiaries**  
**Consolidated Statement of Changes in Equity**  
**For the three months ended March 31, 2025 and 2024**

**Unit: NT\$ thousand**

	Ordinary share capital	Additional paid-in capital	Legal reserves	Undistributed earnings	Exchange difference from translation of the financial statements of foreign operations	Unrealized gains or losses on financial assets at fair value through other comprehensive income	Total equity attributable to owners of the parent company	Non-controllin g interests	Total equity
<b>Balance on January 1, 2024</b>	\$ 1,260,443	1,155,834	216,895	732,111	(2,507)	125,160	3,487,936	467,523	3,955,459
Net income for the period	-	-	-	24,528	-	-	24,528	(11,030)	13,498
Other comprehensive income for the period	-	-	-	-	666	52,587	53,253	1,000	54,253
Total comprehensive income for this period	-	-	-	24,528	666	52,587	77,781	(10,030)	67,751
Changes in ownership interests in subsidiaries	-	(2,137)	-	-	-	-	(2,137)	4,899	2,762
<b>Balance on March 31, 2024</b>	<b>\$ 1,260,443</b>	<b>1,153,697</b>	<b>216,895</b>	<b>756,639</b>	<b>(1,841)</b>	<b>177,747</b>	<b>3,563,580</b>	<b>462,392</b>	<b>4,025,972</b>
<b>Balance on January 1, 2025</b>	\$ 1,310,861	1,150,037	229,009	819,984	(1,338)	48,342	3,556,895	424,171	3,981,066
Net income for the period	-	-	-	31,035	-	-	31,035	(12,894)	18,141
Other comprehensive income for the period	-	-	-	-	528	(37,534)	(37,006)	(2,551)	(39,557)
Total comprehensive income for this period	-	-	-	31,035	528	(37,534)	(5,971)	(15,445)	(21,416)
Increase of non-controlling interests	-	-	-	-	-	-	-	1,048	1,048
<b>Balance on March 31, 2025</b>	<b>\$ 1,310,861</b>	<b>1,150,037</b>	<b>229,009</b>	<b>851,019</b>	<b>(810)</b>	<b>10,808</b>	<b>3,550,924</b>	<b>409,774</b>	<b>3,960,698</b>

(please refer to the attached Notes to the Consolidated Financial Report for details)

**Chairman: Hung-Jen Yang**

**Manager: Ching-Wen Liu**

**Chief Accounting Officer: Ya-Mei Huang**

**ShareHope Medicine Co., Ltd. and its subsidiaries**  
**Consolidated Cash Flow Statement**  
**For the three months ended March 31, 2025 and 2024**

**Unit: NT\$ thousand**

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
<b>Cash flows from (used in) operating activities:</b>		
<b>Net income before tax for the period</b>	\$ 28,767	24,384
<b>Items adjusted:</b>		
Income and expense items		
depreciation expense	64,584	73,272
Amortization expenses	6,111	6,288
Losses on expected credit impairment	2,355	17
Net losses (gains) on financial assets at fair value through profit		
or loss	2,566	(4,225)
Interest expenses	12,435	14,128
Interest income	(1,525)	(985)
Dividend income	(1,085)	(2,444)
Share of (gains) losses of affiliates recognized by the equity		
method	1,029	(463)
Gains on disposal and retirement of properties, plants and		
equipment	(33)	(136)
Total income and expense items	86,437	85,452
<b>Changes in assets/liabilities related to operating activities:</b>		
Notes receivable (including related parties)	2,624	1,328
Accounts receivable (including related parties)	234	62,777
Lease payments receivable (including related parties)	11,140	(8,470)
Other receivables (including related parties)	18,403	(27,806)
Inventories	10,072	10,231
Prepayments	(4,644)	2,843
Other current assets	1,974	(1,518)
Notes payable (including related parties)	153	(6,780)
Accounts payable (including related parties)	(57,146)	(36,993)
Other payables (including related parties)	(101,037)	(66,655)
contract liability	(9,190)	1,624
Other current liabilities	(13,038)	9,241
Net defined benefit liabilities	12	(1,269)
Total net changes in assets and liabilities related to operating	(140,443)	(61,447)
activities		
Cash (outflow) inflow from operation	(25,239)	48,389
Interests received	1,525	985
Interests paid	(12,427)	(13,724)
Income taxes paid	-	(3)
<b>Net cash (outflow) inflow from operating activities</b>	(36,141)	35,647

(please refer to the attached Notes to the Consolidated Financial Report for details)

**Chairman: Hung-Jen Yang**

**Manager: Ching-Wen Liu**

**Chief Accounting Officer:  
Ya-Mei Huang**

**ShareHope Medicine Co., Ltd. and its subsidiaries**  
**Consolidated Cash Flow Statement (Continued)**  
**For the three months ended March 31, 2025 and 2024**

**Unit: NT\$ thousand**

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
<b>Cash flows from (used in) investing activities:</b>		
Acquisition of financial assets at fair value through other comprehensive income	\$ -	(42,510)
Capital returned due to capital reduction in financial assets at fair value through other comprehensive income	888	1,483
Acquisition of financial assets at amortized cost	(26,983)	(16,908)
Acquisition of property, plant and equipment	(29,061)	(24,699)
Disposal of property, plant and equipment	-	18
Loss (gain) on disposal of investment properties	240,000	-
Increase in refundable deposits	(12,057)	(12,980)
Decrease in other receivables-related parties	-	6,990
Acquisition of intangible assets	(1,207)	(3,451)
Decrease in other non-current assets	316	3,115
Dividends received	3,228	2,444
<b>Net cash flows from (used in) investing activities</b>	<b>175,124</b>	<b>(86,498)</b>
<b>Cash flows from (used in) financing activities:</b>		
Increase (decrease) in short-term loans	13,181	(30,460)
Decrease in short-term bills payable	(20,000)	-
Borrowing of long-term loans	836,000	2,550
Repayment of long-term loans	(868,282)	(12,699)
Decrease in deposits received	(2,080)	(803)
Lease principal payment	(28,819)	(30,631)
Changes in non-controlling interests	1,048	2,762
<b>Net cash outflow from financing activities</b>	<b>(68,952)</b>	<b>(69,281)</b>
Impact of exchange rate changes on cash and cash equivalents	837	1,142
Increase (decrease) in cash and cash equivalents for the current period	70,868	(118,990)
Balance of cash and cash equivalents at the beginning of the period	1,459,635	1,383,022
Balance of cash and cash equivalents at the end of the period	<b>\$ 1,530,503</b>	<b>1,264,032</b>
Composition of cash and cash equivalents:		
Cash and cash equivalents reported in the balance sheet	\$ 1,530,503	1,261,724
Cash and cash equivalents classified as disposal groups held for sold	-	2,308
Balance of cash and cash equivalents at the end of the period	<b>\$ 1,530,503</b>	<b>1,264,032</b>

(please refer to the attached Notes to the Consolidated Financial Report for details)

**Chairman: Hung-Jen Yang    Manager: Ching-Wen Liu    Chief Accounting Officer: Ya-Mei Huang**



**ShareHope Medicine Co., Ltd. and its subsidiaries**  
**Notes to Consolidated Financial Statements**  
**For the Three Months Ended March 31, 2025 and 2024**  
**(Unless otherwise specified, all amounts are in thousands of New Taiwan Dollars)**

**I. Company History**

ShareHope Medicine Co., Ltd. (hereinafter referred to as the Company) was established with the approval of the Ministry of Economic Affairs on October 13, 2003, with its registered address at 19th Floor, No. 168 Jingguo Road, Taoyuan District, Taoyuan City. The Company and its subsidiaries (hereinafter referred to as the Consolidated Company) are mainly engaged in wholesale and retail sales of medicines and hygiene materials, leasing of assets for medical institutions to undertake related medical services, and physical examinations for Taiwanese people and foreign labors, on-site medical support services, hemodialysis business management, ophthalmic medical management, clothing-related management services, manufacturing, processing and sales of various non-woven fabrics and management consulting for chain pharmacies in collaboration with medical institutions.

**II. Date and Procedure of the Approval of the Financial Statements**

The Consolidated Financial Statements were approved and issued by the Board of Directors on May 9, 2025.

**III. Application of Newly Issued and Amended Standards and Interpretations**

- (I) The impact of adopting newly issued and amended standards and interpretations approved by the Financial Supervisory Commission

The Consolidated Company adopted the following newly amended terms of the IFRSs on January 1, 2025, which made no significant impact on the Consolidated Financial Statements.

- Amendments to IAS 21 “Lack of Exchangeability”
- Amendments to IFRS 9 and IFRS 7 "Amendment to the Classification and Measurement of Financial Instruments" regarding the application guidance of Section 4.1 of IFRS 9 and the related disclosure requirements under IFRS 7

- (II) Newly issued and amended standards and interpretations that have not yet been approved by the Financial Supervisory Commission

The standards and interpretations that have been issued and amended by the International Accounting Standards Board but have not yet been approved by the Financial Supervisory Commission and may be relevant to the Consolidated Company are as follows:

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

<b>New or amended standards</b>	<b>Major amendment contents</b>	<b>Effective date of standards released by the Board</b>
IFRS 18 "Presentation and Disclosure in Financial Statements"	The new standard introduces three categories of income and expenses, two subtotals of income statement, and a single note on management performance measures. These three amendments and enhanced guidance on how to disaggregate information in financial statements lay the foundation for providing users with better and more consistent information and will affect all companies.	January 1, 2027
IFRS 18 "Presentation and Disclosure in Financial Statements"	<p>· More structured income statement: Under existing standards, companies use different formats to present their operating results, making it difficult for investors to compare the financial performance of different companies. The new standard adopts a more structured income statement, introduces a newly defined subtotal of "operating income," and stipulates that all income and expenses are classified into three new different categories based on the company's main operating activities.</p> <p>· Management Performance Measurement (MPM): The new standard introduces the definition of management performance measurement, and requires the Group to provide the information on each measurement indicator in a single note to the financial statements, and to explain what can provide useful information, how to calculate and how to adjust the measured indicator and the amount recognized in the IFRS accounting standards.</p> <p>• More detailed information: The new standard includes guidance on how companies strengthen the grouping of information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.</p>	January 1, 2027

## **Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

The Consolidated Company is continuously evaluating the impact of above-mentioned standards and interpretations on its financial position and operating results, and the relevant impact will be disclosed when the evaluation is completed.

The Consolidated Company expects that the following unapproved newly issued and amended standards will not have a significant impact on the Consolidated Financial Statements.

- Amendment to "Sales or Investment of Assets between Investors and Their Affiliates or Joint Ventures" under IFRSs 10 and IAS 28
- Amendment to "Insurance Contracts" under IFRSs 17 and amendment to IFRSs 17 IFRS 19 "Subsidiaries without Public Accountability: Disclosures"
- Amendments to IFRS 9 and IFRS 7 "Amendment to the Classification and Measurement of Financial Instruments" regarding the application guidance of Section 3.1 and 3.3 of IFRS 9 and the related disclosure requirements under IFRS 7.
- IFRS Annual Improvements
- Amendments to IFRS 9 and IFRS 7 "Reliance on Natural Energy Contracts"

### **IV. Summary of Major Accounting Policies**

#### **(I) Compliance statement**

These Consolidated Financial Statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to "Regulations") and guidelines of IAS 34 "Interim Financial Reporting" which are endorsed and issued into effect by FSC. The Consolidated Financial Statements do not include all of the information required by the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRSs endorsed by the FSC) for a complete set of the annual Consolidated Financial Statements.

Except for the following accounting policies mentioned below, the significant accounting policies adopted in the Consolidated Financial Statements are the same as those in the Consolidated Financial Statement for the year ended December 31, 2024. For the related information, please refer to Note 4 of the Consolidated Financial Statements for the year ended December 31, 2024.

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

## (II) Consolidation basis

### 1. Subsidiaries Included in Consolidated Financial Statements

Name of investee	Name of subsidiary	Nature of business	Percentage of equity held			Explanation
			2025.3.31	2024.12.31	2024.3.31	
The Company	Chungyuan Medical Management Co., Ltd. (hereinafter referred to as Chungyuan Medical Management)	Management Consulting Services	100.00%	100.00%	100.00%	
The Company	Mytrex Health Technologies Co., Ltd. (hereinafter referred to as Mytrex Health)	Manufacturing and processing of non-woven fabrics and sales of medical and sanitary materials	61.46%	61.46%	61.46%	
The Company	ShareHope Medicine (Hong Kong) Co., Ltd. (hereinafter referred to as ShareHope Hong Kong)	Investment management	100.00%	100.00%	100.00%	
The Company	Minsheng Asia-Pacific (Beijing) Enterprise Management Co., Ltd. (hereinafter referred to as Minsheng Asia-Pacific (Beijing))	Hospital management consulting services	100.00%	100.00%	100.00%	
The Company	Pregetic Medical Health Co., Ltd. (hereinafter referred to as Pregetic Health)	Health management services	38.19%	38.19%	38.90%	Note 3
The Company	Medzoneasia Co., Ltd. (hereinafter referred to as Medzoneasia)	Health management services and hotels	- %	100.00%	91.47%	Note 1
The Company	Shengshi Digital Health Co., Ltd. (hereinafter referred to as Shengshih Technology, formerly known as Shengshih Technology Co., Ltd. )	Management Consulting Services	100.00%	100.00%	100.00%	
The Company	Sheng Tai Food Technology Co., Ltd. (hereinafter referred to as Sheng Tai)	Food and beverage retail	- %	- %	80.00%	Note 6
The Company	YWLT Co., Ltd. (hereinafter referred to as YWLT)	Biotechnology Services	- %	- %	100.00%	Note 7
The Company	Digimed Co., Ltd. (hereinafter referred to as Digimed)	Information software services	60.00%	- %	- %	Note 2
The Company	TECHGROUP Integrate Design Co., Ltd. (hereinafter referred to as TECHGROUP)	Medical information software services	51.00%	- %	- %	Note 2
Medzoneasia	Digimed	Information software services	- %	60.00%	60.00%	Note 2
Medzoneasia	TECHGROUP	Medical information software services	- %	51.00%	51.00%	Note 2

## Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

Mytrex Health Company	Mytrex Industries Inc. (hereinafter referred to as Mytrex)	Manufacturing and processing of non-woven fabrics and sales of medical and sanitary materials	100.00%	100.00%	100.00%	
Mytrex Health Company	Mytrex USA Co. (formerly known as TSVC Co.)	Health care support services	88.89%	88.89%	88.89%	
Mytrex Health Company	Sheng Yo Rehabilitative Technologies, Inc. (hereinafter referred to as Sheng Yo)	Health management services	47.62%	47.62%	47.62%	
Mytrex Health Company	YES Health Co., Ltd. (hereinafter referred to as YES Health)	Wholesale and trading of medicines and management consulting for pharmacies	100.00%	100.00%	100.00%	
YES Health Company	Digimed	Information software services	20.00%	20.00%	20.00%	
ShareHope (Hong Kong) Company	Minsheng (Tianjin) Investment Management Co., Ltd. (hereinafter referred to as Minsheng (Tianjin) Investment)	Investment management	100.00%	100.00%	100.00%	
Pregetic Health Company	Hung-Han Health Business Co., Ltd. (hereinafter referred to as Hung-Han)	Health management services	100.00%	100.00%	100.00%	
Pregetic Health Company	Harvard Health Inc. (hereinafter referred to as Harvard Health, formerly known as Fu Yi Health Management Consulting Co., Ltd.)	Health management services	100.00%	100.00%	100.00%	
Pregetic Health Company	Chinachem Biomedical Co., Ltd. (hereinafter referred to as Chinachem)	Healthcare services	- %	- %	50.00%	Note 4
Hung-Han Company	Macro Global Corporation (hereinafter referred to as Macro Global)	Wholesale and trading of medicines	100.00%	100.00%	100.00%	
Hung-Han Company	Hanting Digital Technology Co., Ltd. (hereinafter referred to as Hanting)	Information software services	- %	- %	66.67%	Note 5
Hung-Han Company	Chinachem	Healthcare services	- %	- %	50.00%	Note 4
Macro Global Corporation	Hanting Company	Information software services	- %	- %	33.33%	Note 5

Note 1: The Company and Medzoneasia conducted a short-form merger in January 2025. After the merger, the Company is the surviving company and Medzoneasia is discontinued.

Note 2: In response to the reorganization of the Group, the investee, Medzoneasia, was merged by the parent company in January 2025. Therefore, the investee was directly held by the Company.

## **Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

Note 3: In September 2024, Pregetic conducted a cash capital increase. However, the Company did not subscribe fully in proportion to its shareholding, which led to a decrease in its shareholding ratio.

Note 4: Pregetic and Hung-Han fully disposed of the equity of Chinachem they held in August 2024, resulting in the loss of control over the subsidiary. Therefore, the Consolidated Company no longer include the gains and expenses in the Consolidated Statement of Comprehensive Income at the time losing control.

Note 5: Hung-Han and Macro Global fully disposed of the equity of Hanting they held in August 2024, resulting in the loss of control over the subsidiary. Therefore, the Consolidated Company no longer include the gains and expenses in the Consolidated Statement of Comprehensive Income at the time losing control.

Note 6: Medzoneasia was dissolved in December 2024.

Note 7: YWLT was dissolved in October 2024.

2. Subsidiaries not included in the consolidated financial statements: None.

### **(III) Employee benefits**

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off event.

### **(IV) Income taxes**

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34 “Interim Reporting.”

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period using the effective annual tax rate as forecasted by the management. Current tax expenses and deferred income tax expenses are recognized proportionally based on the estimated annual current income tax expenses and deferred income tax expenses.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

## **V. Major Sources of Uncertainty in Major Accounting Judgments, Estimates and Assumptions**

The preparation of the Consolidated Financial Statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, estimates, and assumptions about the future (including climate-related risks and opportunities) that affect the application of the accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.

Major sources of the uncertainty in major accounting judgements and estimates made by the management adopting accounting policies of the Consolidated Company in the preparation of the Consolidated Financial Statements were consistent with Note 5 of the Consolidated Financial Statements for the year ended December 31, 2024.

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

## VI. Explanation of Significant Accounting Items

Except for the following disclosures, there were no material differences in the disclosures of significant accounts between the interim Consolidated Financial Statements for the current period and the 2024 Consolidated Financial Statements. Please refer to Note 6 of the 2024 annual Consolidated Financial Statements.

### (I) Cash and cash equivalents

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Cash on hand and working capital	\$ 5,486	5,862	5,856
Cheques, demand deposits and foreign currency deposits	1,461,013	1,343,123	1,205,048
Demand deposits	9,298	54,015	-
Cash equivalents - repurchase bonds	54,706	56,635	50,820
	<u>\$ 1,530,503</u>	<u>1,459,635</u>	<u>1,261,724</u>

### (II) Financial assets at fair value through profit or loss

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
<b>Financial assets mandatorily measured at fair value through profit or loss:</b>			
Non-derivative financial assets			
Fund beneficiary certificates	\$ 10,650	10,610	10,497
Non-TWSE/TPEX listed stocks	25,247	27,853	22,823
Limited partnership interests	-	-	25,439
	<u>\$ 35,897</u>	<u>38,463</u>	<u>58,759</u>
Current	\$ 10,650	10,610	10,497
Non-current	25,247	27,853	48,262
	<u>\$ 35,897</u>	<u>38,463</u>	<u>58,759</u>

Please refer to Note 6 (29) for the amount recognized in profit or loss based on fair value remeasurement.

### (III) Financial assets at fair value through other comprehensive income

Equity instruments at fair value through other comprehensive income:

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Stocks issued by non-TWSE/TPEX listed companies	\$ 299,889	299,873	368,773
Stocks issued by non-listed foreign companies	300,269	345,774	410,389
Limited partnership interests	119,948	125,039	119,062
	<u>\$ 720,106</u>	<u>770,686</u>	<u>898,224</u>

The investments in equity instruments are held by the Combined Company as long-term strategic investments and not for trading purposes, and thus they have been designated to be

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

measured at fair value through other comprehensive income.

Please refer to Note 6 (30) for credit risk and market risk information.

(IV) Notes and accounts receivable and finance lease receivables - current

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Notes receivable	\$ 8,696	11,320	10,945
Accounts receivable - measured at amortized cost	273,034	263,680	281,814
Accounts receivable-related parties - measured at amortized cost	952,921	972,101	1,030,918
Accounts receivable-finance lease payments - measured at amortized cost	-	-	194
Accounts receivable-related parties - finance lease payments - measured at amortized cost	11,907	12,159	14,593
Less: loss allowances	(19,993)	(17,628)	(7,701)
Unrealized interest income	(960)	(1,013)	(1,553)
	<b><u>\$ 1,225,605</u></b>	<b><u>1,240,619</u></b>	<b><u>1,329,210</u></b>

The Consolidated Company estimates the expected credit losses on notes and accounts receivable and financial lease receivables (including related parties) by a simplified approach, that is by measuring lifetime expected credit losses. For this purpose, such notes and accounts receivable and financial lease receivables (including related parties) are grouped based on the common credit risk characteristics that represent customers' abilities to pay all amounts due under contractual terms, with forward-looking information incorporated, including overall economic and related industry information.

The expected credit losses on notes and accounts receivable and finance lease receivables (including related parties) of the Combined Company are analyzed as follows:

	<b>2025.3.31</b>	
	<b>Carrying amount of notes and accounts receivable and finance leases receivable (including related parties)</b>	<b>Loss allowance for expected credit losses during lifetime</b>
Not overdue	\$ 1,146,290	0%
Less than 60 days overdue	42,392	0%~10%
61~90 days overdue	6,508	0%~100%
91~120 days overdue	2,413	0%~100%
More than 121 days overdue	47,995	0%~100%
	<b><u>\$ 1,245,598</u></b>	<b><u>19,993</u></b>



**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

	<b>2024.12.31</b>		
	<b>Carrying amount of notes and accounts receivable and finance leases receivable (including related parties)</b>	<b>Weighted average expected credit loss rate</b>	<b>Loss allowance for expected credit losses during lifetime</b>
Not overdue	\$ 1,186,916	0%~0.02%	217
Less than 60 days overdue	7,668	0%~10%	268
61~90 days overdue	2,360	0%~100%	267
91~120 days overdue	4,721	0%~100%	946
More than 121 days overdue	56,582	0%~100%	15,930
	<b><u>\$ 1,258,247</u></b>		<b><u>17,628</u></b>

	<b>2024.3.31</b>		
	<b>The Carrying Amount of Notes and Accounts Receivable and Finance Lease Receivables</b>	<b>Weighted average expected credit loss rate</b>	<b>Loss allowance for expected credit losses during lifetime</b>
Not overdue	\$ 1,269,783	0%~0.02%	236
Less than 60 days overdue	20,981	0%~10.00%	434
61~90 days overdue	8,160	0%~100%	481
91~120 days overdue	3,970	0%~100%	860
More than 121 days overdue	34,017	0%~100%	5,690
	<b><u>\$ 1,336,911</u></b>		<b><u>7,701</u></b>

The changes in the loss allowances for notes and accounts receivable and finance lease receivables (including related parties) of the Combined Company are analyzed in the table below:

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Beginning balance	\$ 17,628	7,657
Impairment loss	2,355	17
Foreign currency translation gains and losses	10	27
Ending balance	<b><u>\$ 19,993</u></b>	<b><u>7,701</u></b>

(V) Other receivables

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Receivables from chain pharmacies	\$ 15,261	25,463	27,178
Other receivables - related parties	27,989	268,252	23,864
Others	15,285	25,366	39,607
Less: loss allowances	-	-	(882)
	<b><u>\$ 58,535</u></b>	<b><u>319,081</u></b>	<b><u>89,767</u></b>

The table of changes in loss allowances for other receivables of the Consolidated Company is as follows:

	<b>For the three months ended March 31, 2024</b>
Beginning balance	\$ 865
Foreign currency translation gains and losses	17
Ending balance	<b><u>\$ 882</u></b>

Please refer to Note 6 (30) for other credit risk information.

(VI) Finance lease receivables

The Consolidated Company subleases machinery and equipment for a period of two to ten years, with an implied interest rate of 2% to 12.23% under the lease agreements, covering the entire remaining period of the main lease agreement. Therefore, such subleases are classified as finance leases.

The maturity analysis of lease payments is presented in the following table based on the undiscounted lease payments to be received after the reporting date:

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Less than one year	\$ 11,908	12,160	14,787
1~2 years	5,370	5,911	10,245
2~3 years	3,099	3,314	3,652
3~4 years	2,528	2,928	1,770
4~5 years	1,329	1,329	1,199
More than 5 years	3,324	3,656	-
Gross investment in the lease	27,558	29,298	31,653
Unearned finance income	(1,990)	(2,183)	(2,760)
Present value of lease payments receivable	<u><u>\$ 25,568</u></u>	<u><u>27,115</u></u>	<u><u>28,893</u></u>
Current	\$ 10,947	11,146	13,234
Non-current	14,621	15,969	15,659
	<u><u>\$ 25,568</u></u>	<u><u>27,115</u></u>	<u><u>28,893</u></u>

The Consolidated Company estimates the financial lease receivables by a simplified approach, that is by measuring lifetime expected credit losses. For this purpose, such financial lease receivables are grouped based on the characteristics of the credit risks related to the ability to pay all amounts due under contractual terms, with forward-looking information incorporated, including overall economic and related industry information.

No loss allowance had to be provisioned due to increased risk of expected credit losses on the financial lease receivables of the Consolidated Company on March 31, 2025, December 31 and March 31, 2024.

**(VII) Inventory**

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Medicines and medical materials	\$ 27,965	31,358	34,140
Raw materials	24,872	22,186	22,753
Work in progress	1,552	3,177	42
Finished products	18,294	22,379	23,991
Goods	209,501	211,606	204,984
Medical equipment	-	1,550	333
	<u><u>\$ 282,184</u></u>	<u><u>292,256</u></u>	<u><u>286,243</u></u>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

Particulars of cost of sales are as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Cost of inventories sold	\$ 755,022	688,870
Inventory falling price loss (recovery benefit)	(170)	(38)
Obsolete inventories	106	234
Scrap income	(167)	(164)
Inventory loss	-	101
Others	2,582	(599)
	<b><u>\$ 757,373</u></b>	<b><u>688,404</u></b>

(VIII) Non-current assets held for sale

In March 2024, the Consolidated Company's subsidiary, Mytrex Health, obtained a letter of intent to acquire equity in Sheng Yo Rehabilitative Technologies, Inc. at a transaction price of NT\$6,400 thousand, with the delivery date set for April 1, 2024. Then, the transaction was reported to the Board of Directors and Audit Committee on May 10, 2024. Per the resolution by the Board of Directors and Audit Committee, they should be bought back at the same selling price and then re-sold at appropriate price. As of March 31, 2024, the assets and liabilities of the disposal group available-for-sale amounted to NT\$56,043 thousand and NT\$43,176 thousand respectively. The details are as follows:

	<b>2024.3.31</b>
Cash and cash equivalents	\$ 2,308
Accounts receivable	2,783
Other receivables	5,247
Prepayments	220
Other current assets	715
Property, plant and equipment	2,936
Right-of-use assets, net	19,504
Intangible assets, net	215
Refundable deposits	12,370
Other non-current assets	9,745
Assets included in a group held for sale	<b><u>\$ 56,043</u></b>
Short-term loans and long-term loans due within one year	\$ 13,917
Other payables (\$100 thousand arising from related party transactions has been written off)	913
Other current liabilities	14
Long-term loans	4,932
lease liabilities	23,400
Liabilities included in a disposal group held for sale	<b><u>\$ 43,176</u></b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(IX) Changes in ownership interests in subsidiaries

1. No participation in subsidiaries' cash capital increase without loss of control

The Consolidated Company did not subscribe for shares in the cash capital increase by -Sheng Yo Rehabilitative Technologies, Inc. based on its shareholding ratio in January 2024, resulting in a decrease in its shareholding ratio from 90.91% to 47.62%.

	<b>For the three months ended March 31, 2024</b>
Decrease in equity attributable to subsidiaries after issuance of new shares	\$ 4,240
Undistributed earnings	<u><u>\$ 4,240</u></u>

The impact of the above transaction on The Company is as follows:

	<b>For the three months ended March 31, 2024</b>
Additional paid-in capital - changes in ownership interests in subsidiaries	<u><u>\$ (2,137)</u></u>

(X) Subsidiaries with significant non-controlling interests

Non-controlling interests in subsidiaries that are material to the Combined Company are as follows:

Name of subsidiary	Principal place of business/country of incorporation	Proportion of ownership interest and voting rights of non-controlling interests		
		2025.3.31	2024.12.31	2024.3.31
Mytrex Health Company	Taiwan	38.54%	38.54%	38.54%
TECHGROUP Integrate Design Co., Ltd.	Taiwan	49.00%	49.00%	49.00%
Medzoneasia	Taiwan	- %	- %	8.53%
Pregetic Health Company	Taiwan	61.81%	61.81%	61.10%

## Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

The consolidated financial information of the above-mentioned subsidiaries, which is prepared in accordance with IFRSs recognized by the Financial Supervisory Commission and presents the amount before transactions among the Consolidated companies are written off, is as follows:

The consolidated financial information of Mytrex Health Company:

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Current assets	\$ 199,344	110,495	120,144
Non-current assets	413,511	500,292	558,109
Current liabilities	(8,658)	(10,041)	(10,053)
Non-current liabilities	(548)	(572)	(305)
Net assets	<b><u>\$ 603,649</u></b>	<b><u>600,174</u></b>	<b><u>667,895</u></b>
Carrying amount of non-controlling interests at the end of the period	<b><u>\$ 254,965</u></b>	<b><u>253,626</u></b>	<b><u>279,725</u></b>

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Operating revenue	<b><u>\$ -</u></b>	<b><u>-</u></b>
Net loss for the period	\$ (2,383)	(4,922)
Other comprehensive income	5,858	1,451
Total comprehensive income	<b><u>\$ 3,475</u></b>	<b><u>(3,471)</u></b>
Net loss for the period attributable to non-controlling interests	<b><u>\$ (918)</u></b>	<b><u>(1,897)</u></b>
Total comprehensive income attributable to non-controlling interests	<b><u>\$ 1,339</u></b>	<b><u>(1,338)</u></b>

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Cash flows from investing activities	\$ 89,622	46,138
Cash flows from financing activities	(35,952)	(35,000)
Effects of exchange rate	137	417
Increase in cash and cash equivalents	<b><u>\$ 53,807</u></b>	<b><u>11,555</u></b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

The consolidated financial information of TECHGROUP Integrate Design Co., Ltd.:

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Current assets	\$ 41,149	44,373	40,380
Non-current assets	1,945	2,309	3,038
Current liabilities	(21,561)	(25,357)	(16,809)
Non-current liabilities	-	-	(535)
Net assets	<b>\$ 21,533</b>	<b>21,325</b>	<b>26,074</b>
Carrying amount of non-controlling interests at the end of the period	<b>\$ 14,789</b>	<b>15,393</b>	<b>19,839</b>

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Operating revenue	<b>\$ 15,017</b>	<b>17,143</b>
Net income for the period	\$ 208	4,543
Other comprehensive income	-	-
Total comprehensive income	<b>\$ 208</b>	<b>4,543</b>
Net income for the period attributable to non-controlling interests	<b>\$ (604)</b>	<b>1,520</b>
Total comprehensive income attributable to non-controlling interests	<b>\$ (604)</b>	<b>1,520</b>

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Cash flows from operating activities	\$ (7,690)	(3,303)
Cash flows from investing activities	5	(166)
Cash flows from financing activities	(227)	(221)
Decrease in cash and cash equivalents	<b>\$ (7,912)</b>	<b>(3,690)</b>

Consolidated financial information of Medzoneasia:

	<b>2024.3.31</b>
Current assets	\$ 34,486
Non-current assets	178,376
Current liabilities	(57,504)
Non-current liabilities	(37,258)
Net assets	<b>\$ 118,100</b>
Carrying amount of non-controlling interests at the end of the period	<b>\$ 10,074</b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

	<b>For the three months ended March 31, 2024</b>
Operating revenue	<u><u>\$ 7,972</u></u>
Net loss for the period	\$ (7,330)
Other comprehensive income	(10,200)
Total comprehensive income	<u><u>\$ (17,530)</u></u>
Net loss for the period attributable to non-controlling interests	<u><u>\$ (625)</u></u>
Total comprehensive income attributable to non-controlling interests	<u><u>\$ (1,495)</u></u>

	<b>For the three months ended March 31, 2024</b>
Cash flows from operating activities	\$ 3,038
Cash flows from financing activities	(18,636)
Decrease in cash and cash equivalents	<u><u>\$ (15,598)</u></u>

The consolidated financial information of Pregetic Health:

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Current assets	\$ 70,131	92,761	60,933
Non-current assets	322,654	345,008	354,944
Current liabilities	(163,589)	(179,605)	(140,279)
Non-current liabilities	(28,542)	(32,309)	(50,088)
Net assets	<u><u>\$ 200,654</u></u>	<u><u>225,855</u></u>	<u><u>225,510</u></u>
Carrying amount of non-controlling interests at the end of the period	<u><u>\$ 129,670</u></u>	<u><u>145,246</u></u>	<u><u>143,520</u></u>

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Operating revenue	<u><u>\$ 6,180</u></u>	<u><u>10,315</u></u>
Net loss for the period	\$ (17,389)	(14,302)
Other comprehensive income	(7,811)	2,039
Total comprehensive income	<u><u>\$ (25,200)</u></u>	<u><u>(12,263)</u></u>
Net loss for the period attributable to non-controlling interests	<u><u>\$ (10,748)</u></u>	<u><u>(8,756)</u></u>
Total comprehensive income attributable to non-controlling interests	<u><u>\$ (15,577)</u></u>	<u><u>(7,509)</u></u>



# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

	For the three months ended March 31, 2025	For the three months ended March 31, 2024
Cash flows from operating activities	\$ (8,694)	9,896
Cash flows from investing activities	(1,004)	1,503
Cash flows from financing activities	(3,912)	(7,146)
Increase (decrease) in cash and cash equivalents	<u><u>\$ (13,610)</u></u>	<u><u>4,253</u></u>

## (XI) Property, plant and equipment

	Land	Houses and buildings	Machinery and equipment	Transportation equipment	Office equipment	Leasehold improvements	Building improvement	Other equipment	Leased assets	Unfinished projects and equipment to be accepted	Total
Cost:											
Balance on January 1, 2025	\$ 651,352	514,180	525,073	2,183	102,765	211,124	24,562	95,926	436,800	-	2,563,965
Increase	-	-	1,530	-	307	-	-	6,367	8,762	23,631	40,597
Disposal	-	-	-	-	(1)	-	-	-	(9,162)	-	(9,163)
Reclassification	-	-	-	-	-	-	(24,562)	34,208	-	(9,646)	-
Effects of changes in foreign exchange rates	-	-	-	-	1	-	-	-	-	-	1
Balance on March 31, 2025	<u>\$ 651,352</u>	<u>514,180</u>	<u>526,603</u>	<u>2,183</u>	<u>103,072</u>	<u>211,124</u>	<u>-</u>	<u>136,501</u>	<u>436,400</u>	<u>13,985</u>	<u>2,595,400</u>
Balance on January 1, 2024	\$ 665,253	530,326	522,540	2,183	100,057	230,221	-	86,655	469,262	-	2,606,497
Increase	-	-	-	-	635	2,135	-	758	5,966	946	10,440
Classified as non-current assets held for sale	-	-	-	-	-	(2,433)	-	(758)	-	-	(3,191)
Disposal	-	-	(5,712)	-	(2)	(838)	-	(3)	(13,277)	-	(19,832)
Effects of changes in foreign exchange rates	-	-	-	-	1	-	-	-	-	-	1
Balance on March 31, 2024	<u>\$ 665,253</u>	<u>530,326</u>	<u>516,828</u>	<u>2,183</u>	<u>100,691</u>	<u>229,085</u>	<u>-</u>	<u>86,652</u>	<u>461,951</u>	<u>946</u>	<u>2,593,915</u>
Accumulated depreciation and impairment:											
Balance on January 1, 2025	\$ -	44,276	469,236	1,632	74,345	160,982	-	54,613	268,652	-	1,073,736
Depreciation for the year	-	4,285	5,599	159	3,321	4,269	-	2,238	15,298	-	35,169
Disposal	-	-	-	-	(1)	-	-	-	(9,162)	-	(9,163)
Reclassification	-	-	(171)	-	-	-	-	171	-	-	-
Effects of changes in foreign exchange rates	-	-	-	-	1	-	-	-	-	-	1
Balance on March 31, 2025	<u>\$ -</u>	<u>48,561</u>	<u>474,664</u>	<u>1,791</u>	<u>77,666</u>	<u>165,251</u>	<u>-</u>	<u>57,022</u>	<u>274,788</u>	<u>-</u>	<u>1,099,743</u>
Balance on January 1, 2024	\$ -	35,881	396,507	996	62,243	148,098	-	47,554	238,667	-	929,946
Depreciation for the year	-	4,562	8,340	159	3,494	6,445	-	1,510	16,546	-	41,056
Classified as non-current assets held for sale	-	-	-	-	-	(217)	-	(38)	-	-	(255)
Disposal	-	-	(5,712)	-	(2)	(641)	-	(3)	(13,277)	-	(19,635)
Effects of changes in foreign exchange rates	-	-	-	-	1	-	-	-	-	-	1
Balance on March 31, 2024	<u>\$ -</u>	<u>40,443</u>	<u>399,135</u>	<u>1,155</u>	<u>65,736</u>	<u>153,685</u>	<u>-</u>	<u>49,023</u>	<u>241,936</u>	<u>-</u>	<u>951,113</u>
Book value:											
March 31, 2025	<u>\$ 651,352</u>	<u>465,619</u>	<u>51,939</u>	<u>392</u>	<u>25,406</u>	<u>45,873</u>	<u>-</u>	<u>79,479</u>	<u>161,612</u>	<u>13,985</u>	<u>1,495,657</u>
December 31, 2024	<u>\$ 651,352</u>	<u>469,904</u>	<u>55,837</u>	<u>551</u>	<u>28,420</u>	<u>50,142</u>	<u>24,562</u>	<u>41,313</u>	<u>168,148</u>	<u>-</u>	<u>1,490,229</u>
2024											
March 31, 2024	<u>\$ 665,253</u>	<u>489,883</u>	<u>117,693</u>	<u>1,028</u>	<u>34,955</u>	<u>75,400</u>	<u>-</u>	<u>37,629</u>	<u>220,015</u>	<u>946</u>	<u>1,642,802</u>

## Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

Please refer to Note 8 for details of long-term loan guarantees that have been provided as of March 31, 2025, December 31 and March 31, 2024.

### (XII) Right-of-use assets

	<u>Houses and buildings</u>	<u>Transport ation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Total</u>
Cost:					
Balance on January 1, 2025	\$ 557,553	16,208	-	400	574,161
Increase	-	274	2,191	-	2,465
Disposal	(5,015)	(547)	-	-	(5,562)
Balance on March 31, 2025	<b><u>\$ 552,538</u></b>	<b><u>15,935</u></b>	<b><u>2,191</u></b>	<b><u>400</u></b>	<b><u>571,064</u></b>
Balance on January 1, 2024	\$ 561,411	22,523	-	-	583,934
Classified as non-current assets held for sale	(22,372)	-	-	-	(22,372)
Disposal	-	(496)	-	-	(496)
Reclassification	6	(6)	-	-	-
Balance on March 31, 2024	<b><u>\$ 539,045</u></b>	<b><u>22,021</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>561,066</u></b>
Accumulated depreciation:					
Balance on January 1, 2025	\$ 216,529	7,539	-	33	224,101
Increase	14,737	1,517	73	50	16,377
Disposal	(2,089)	(547)	-	-	(2,636)
Balance on March 31, 2025	<b><u>\$ 229,177</u></b>	<b><u>8,509</u></b>	<b><u>73</u></b>	<b><u>83</u></b>	<b><u>237,842</u></b>
Balance on January 1, 2024	\$ 162,326	13,818	-	-	176,144
Increase	15,248	1,965	-	-	17,213
Classified as non-current assets held for sale	(2,868)	-	-	-	(2,868)
Disposal	-	(496)	-	-	(496)
Balance on March 31, 2024	<b><u>\$ 174,706</u></b>	<b><u>15,287</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>189,993</u></b>
Book value:					
March 31, 2025	<b><u>\$ 323,361</u></b>	<b><u>7,426</u></b>	<b><u>2,118</u></b>	<b><u>317</u></b>	<b><u>333,222</u></b>
December 31, 2024	<b><u>\$ 341,024</u></b>	<b><u>8,669</u></b>	<b><u>-</u></b>	<b><u>367</u></b>	<b><u>350,060</u></b>
March 31, 2024	<b><u>\$ 364,339</u></b>	<b><u>6,734</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>371,073</u></b>

### (XIII) Investment property

Investment properties comprise self-owned assets held by the Consolidated Company, office buildings leased to third parties under operating leases, and right-of-use assets that evidence leasehold rights. The original non-cancellable period of leased investment

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

properties is one to five years, and the rental income from leased investment properties is fixed.

	<u>Land and improvements</u>	<u>Houses and buildings</u>	<u>Right-of-use asset</u>	<u>Total</u>
March 31, 2025	\$ -	-	96,893	96,893
December 31, 2024	\$ -	-	111,884	111,884
March 31, 2024	\$ 152,641	24,113	146,437	323,191

The investment properties of the Consolidated Company had no significant addition, disposition, impairment, or reversal for the three months ended March 31, 2025 and 2024. Please refer to Note 12 for the amount of depreciation, and for other related information, please refer to Note 6 (13) of the Consolidated Financial Statements for the year ended December 31, 2024.

There was no significant difference between the fair value of investment properties of the Consolidated Company and the information disclosed in Note 6 (13) of the Consolidated Financial Statements for the year ended December 31, 2024.

Please refer to Note 6 (20) for the Consolidated Company's renting of investment properties under operating leases.

Please refer to Note 8 for the amount of the Consolidated Company's investment properties with collateral as loan guarantee.

## (XIV) Intangible assets

	<u>Management right</u>	<u>Trademark right</u>	<u>Customer relation</u>	<u>Lease contract</u>	<u>Goodwill</u>	<u>Computer software</u>	<u>Technology authorization</u>	<u>Benefit of cession</u>	<u>Others</u>	<u>Total</u>
Book value:										
Balance on March 31, 2025	\$ 494	93,245	14,717	3,857	165,517	30,330	-	9,976	94	318,230
Balance on December 31, 2024	\$ 572	93,245	16,734	4,025	165,517	31,385	125	10,410	107	322,120
Balance on March 31, 2024	\$ 805	93,145	22,786	4,528	165,517	34,789	-	12,187	147	333,904

The intangible assets of the Consolidated Company had no significant addition, disposition, impairment, or reversal for the three months ended March 31, 2025 and 2024. Please refer to Note 12 for the amount of amortization, and for other related information, please refer to Note 6 (14) of the Consolidated Financial Statements for the year ended December 31, 2024.

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(XV) Other non-current assets

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Refundable deposits	\$ 480,852	468,795	432,861
Prepayments for equipment and engineering	719	1,933	6,338
Net defined benefit assets - non-current	7,054	7,007	5,164
Long-term prepayments	7,746	8,049	5,421
Others	863	906	702
	<u><u>\$ 497,234</u></u>	<u><u>486,690</u></u>	<u><u>450,486</u></u>

Refundable deposits are operational deposits paid by the Consolidated Company to ensure the performance of obligations of providing medical system institutions with operations management services.

(XVI) Short-term loans

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Unsecured bank loans	\$ 339,268	321,087	287,007
Secured bank loans	107,000	112,000	80,000
	<u><u>\$ 446,268</u></u>	<u><u>433,087</u></u>	<u><u>367,007</u></u>
Interest rate range	<u>2.00%~3.757%</u>	<u>2.00%~3.709%</u>	<u>1.87%~4.08%</u>
Unused quota	<u><u>\$ 1,203,737</u></u>	<u><u>1,223,271</u></u>	<u><u>1,227,351</u></u>

For the three months ended March 31, 2025 and 2024, the amount of addition was NT\$274,161 thousand and NT\$186,297 thousand, respectively; the range of interest rate was from 2.00% to 3.76% and from 1.87% to 3.56%, respectively; the month of expiration was from April 2025 to March 2026 and from February 2024 to March 2025, respectively; the amount of repayment was NT\$260,980 thousand and NT\$216,757 thousand, respectively.

Please refer to Note 8 for guaranty provided by the Consolidated Company for bank loans with assets as collateral.

(XVII) Short-term bills payable

	<u>2025.3.31</u>		<u>2024.12.31</u>		<u>2024.3.31</u>	
	<u>Interest rate</u>	<u>amount</u>	<u>Interest rate</u>	<u>amount</u>	<u>Interest rate</u>	<u>amount</u>
Commercial paper payable	2.55%	35,000	2.55%	55,000	2%	55,000
Less: discount on short-term bills payable		<u>(53)</u>		<u>(185)</u>		<u>(6)</u>
		<u><u>\$ 34,947</u></u>		<u><u>54,815</u></u>		<u><u>54,994</u></u>
Unused quota		<u><u>\$ 60,000</u></u>		<u><u>60,000</u></u>		<u><u>60,000</u></u>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(XVIII) Long-term loans

<b>2025.3.31</b>				
	<b>Currency</b>	<b>Interest rate range</b>	<b>Expiration month</b>	<b>amount</b>
Secured bank loans	NT\$	2.22%~3.99%	2026.5~2039.12	\$ 978,111
Less: amount due within one year				<u>(99,649)</u>
				<u><b>\$ 878,462</b></u>
Unused quota				<u><b>\$ 15,918</b></u>
<b>2024.12.31</b>				
	<b>Currency</b>	<b>Interest rate range</b>	<b>Expiration month</b>	<b>amount</b>
Secured bank loans	NT\$	1.99%~3.99%	2026.05~2031.4	\$ 1,010,393
Less: amount due within one year				<u>(185,158)</u>
				<u><b>\$ 825,235</b></u>
Unused quota				<u><b>\$ 625,865</b></u>
<b>2024.3.31</b>				
	<b>Currency</b>	<b>Interest rate range</b>	<b>Expiration month</b>	<b>amount</b>
Secured bank loans	NT\$	1.71%~3.165%	2025.11~2031.4	\$ 1,107,887
Less: amount due within one year				<u>(115,947)</u>
				<u><b>\$ 991,940</b></u>
Unused quota				<u><b>\$ 620,000</b></u>

The consolidated company's long-term borrowings increased by NT\$836,000 thousand from January 1 to March 31, 2025, with interest rates ranging from 2.22% to 3.99%. The maturity dates range from November 2025 to December 2039. The amount repaid was NT\$868,282 thousand. There were no significant issuances, repurchases, or repayments from January 1 to March 31, 2024. Please refer to Note 6(29) for interest expense details.

Please refer to Note 8 for guaranty provided by the Consolidated Company for bank loans with assets as collateral.

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(XIX) Lease liabilities

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Current	<u><b>\$ 104,611</b></u>	<u><b>109,778</b></u>	<u><b>115,511</b></u>
Non-current	<u><b>\$ 353,314</b></u>	<u><b>379,196</b></u>	<u><b>421,434</b></u>

Please refer to Note 6 (30) Financial Instruments for maturity analysis.

The following amounts are recognized in profit or loss:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Interest expenses on lease liabilities	<u><b>\$ 2,425</b></u>	<u><b>2,941</b></u>
Variable lease payments not included in the measurement of the lease liabilities	<u><b>\$ 4,806</b></u>	<u><b>4,154</b></u>
Income from sublease of right-of-use assets	<u><b>\$ 19,570</b></u>	<u><b>20,522</b></u>
Expenses on short-term leases and low-value leases	<u><b>\$ 1,818</b></u>	<u><b>2,281</b></u>

The following amounts are recognized in the cash flow statement:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Total cash outflows for leases	<u><b>\$ 37,868</b></u>	<u><b>40,007</b></u>

1. Houses and buildings

The Consolidated Company leases houses, buildings, and transportation equipment for plants, operation, and sublease, typically for a lease term of 1~11 years. It is agreed that the Consolidated Company shall not lend, sublease, transfer or otherwise hand over the lease object to other parties without the consent of the lessor during the lease term, and part of the leases include the option to extend the lease term by the same period as the lease term of the original contract upon expiration of the leases.

Please refer to Note 6(20) for the Consolidated Company's subleasing of part of the right-of-use assets with the consent of the lessor under operating leases.

2. Other leases

The Combined Company leases some buildings and transportation equipment which are short-term or low value leases, and elects not to recognize related right-of-use assets and lease liabilities by applying recognition exemption.

## Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

### (XX) Operating lease

The Consolidated Company leases self-owned property, plant and equipment, investment properties and right-of-use assets. Since substantially all the risks and rewards attached to the ownership of the underlying assets have not been transferred, such lease contracts are classified as operating leases. Please refer to Note 6 (11) Property, Plant and Equipment, (12) Right-of-use Assets and (13) Investment Properties respectively for details.

The maturity analysis of lease payments is presented in the following table based on the total undiscounted lease payments to be received after the reporting date:

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
1st year	\$ 144,001	158,896	201,302
2nd year	24,010	31,899	62,610
3rd year	3,322	3,920	29,531
4th year	414	465	24,349
5th year	31	123	23,930
More than 5 years	-	-	95,485
Total undiscounted lease payments	<u><u>\$ 171,778</u></u>	<u><u>195,303</u></u>	<u><u>437,207</u></u>

### (XXI) Other payables

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Employee remuneration payable	\$ 58,379	92,419	81,701
Salaries and bonuses payable	47,257	78,107	48,094
Equipment payables	14,448	3,141	2,843
Directors' and supervisors' remuneration payable	4,528	4,048	3,625
Business tax payable	2,656	10,817	2,266
Others	59,323	63,073	73,092
	<u><u>\$ 186,591</u></u>	<u><u>251,605</u></u>	<u><u>211,621</u></u>

### (XXII) Employee benefits

#### 1. Defined benefit plans

Since there was no material volatility of the market, material curtailments, settlements, or other significant one-off event that occurred subsequent to the end of prior fiscal year, the pension cost in the accompanying interim consolidated financial statements was measured and disclosed according to the actuarially determined pension cost as of December 31, 2024 and 2023.

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Operating costs	\$ 46	46
Operating expenses	74	74
	<b><u>\$ 120</u></b>	<b><u>120</u></b>

2. Defined contribution plans

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Operating costs	\$ 1,740	1,498
Operating expenses	3,380	4,073
	<b><u>\$ 5,120</u></b>	<b><u>5,571</u></b>

(XXIII) Income tax

1. The income tax expenses of the Consolidated Company are as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Income tax expenses for the period	\$ 11,254	10,909
Deferred tax income	(628)	(23)
income tax expense	<b><u>\$ 10,626</u></b>	<b><u>10,886</u></b>

2. The details of the income tax (expenses) benefits recognized by the Consolidated Company under other comprehensive income are as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Items not reclassified to profit or loss:		
Equity instruments at fair value through other comprehensive income	<b><u>\$ 9,536</u></b>	<b><u>(13,250)</u></b>



**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Items that may be reclassified to profit or loss subsequently:		
Exchange difference from translation of the financial statements of foreign operations	<b>\$ (129)</b>	<b>(206)</b>

3. Declaration and approval of the Combined Company's income tax settlement for profit-making business are as follows:

<b>Name of company</b>	<b>Year of approval</b>
The Company	2023
Chungyuan Medical Management Company	2023
TECHGROUP Integrate Design Co., Ltd.	2023
Mytrex Health Company	2023
Macro Global Corporation	2023
YES Health Company	2022
Pregetic Health Company	2023
Mytrex	2023
Shengshih Technology Co., Ltd.	2023
Hung-Han Company	2023
Harvard Health Company (formerly known as Fuyi Company)	2023
Digimed	2023

**(XXIV) Capital and other equity**

Except for the following disclosures, there was no significant change in capital and other equity of the Consolidated Company for the three months ended March 31, 2025 and 2024. For other related information, please refer to Note 6 (24) of the Consolidated Financial Statements for the year ended December 31, 2024.

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

1. Capital reserve

	<u>2025.3.31</u>	<u>2024.12.31</u>	<u>2024.3.31</u>
Premium on issuance of stocks and conversion of corporate bonds	\$ 1,095,196	1,095,196	1,095,196
The difference between the price and book value of subsidiaries' equity actually acquired and disposed of	45,810	45,810	35,327
Recognized changes in ownership interests in subsidiaries	2,235	2,235	16,378
Lapsed share option	2,896	2,896	2,896
Share option for convertible corporate bonds	3,900	3,900	3,900
	<u><u>\$ 1,150,037</u></u>	<u><u>1,150,037</u></u>	<u><u>1,153,697</u></u>

2. Retained earnings

As per the Company's Articles of Incorporation, a surplus in the annual final accounts shall first be appropriated to pay taxes to cover accumulated losses, and then 10% of the surplus shall be appropriated as legal reserves, excluding the case where legal reserves have reached the total capital of the Company. The remaining part shall be appropriated or reversed as special reserves according to the laws and regulations. In case of any surplus remained thereafter, the Board of Directors shall prepare a shareholder dividend distribution proposal and submit it to the shareholders' regular meeting for resolution on the distribution of dividends to shareholders with surplus and accumulated undistributed earnings.

In consideration of the current and future investment environment, capital needs, profitability, capital structure, future operational needs, as well as the interests of shareholders, balanced dividends and the Company's long-term financial plan, etc., dividends will be distributed in cash or stock. The proportion of dividends distributed in cash to shareholders in the current year shall be no less than 20% of the total dividends in the current year, while the rest shall be distributed in stock dividends. However, the actual distribution proportion may be adjusted according to the actual profit and operating conditions of the current year.

(1) Special reserves

In accordance with the regulations of the Financial Supervisory Commission, for the distribution of distributable earnings, the Company shall appropriate a special reserve from the current profit and loss and the undistributed earnings in the previous period for the difference between the recognized net deduction of other shareholders'

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

equity in the current year and the balance of the special reserve appropriated in the preceding paragraph. The deduction of other shareholders' equity accumulated in the previous period shall be appropriated from undistributed earnings in the previous period to a special reserve and shall not be distributed. If there is a subsequent reversal in the deduction of other shareholders' equity, the reversed amount shall be used for distribution of earnings.

(2) Distribution of earnings

The resolutions on the distribution of earnings for 2024 was approved by the Board of Directors of the Company on March 14, 2025, and the amounts of dividends distributed to owners are as follows:

		<b>2024</b>	
		<b>Allotment rate</b>	
		<b>(NT\$)</b>	<b>Amount</b>
Dividends distributed to ordinary shareholders:			
Cash	\$	0.50	65,543
Stocks		0.50	65,543
		<b>\$</b>	<b><u>131,086</u></b>

The resolutions on the distribution of earnings for 2023 was approved by the shareholders' meetings of the Company on June 24, 2024, and the amounts of dividends distributed to owners are as follows:

		<b>2023</b>	
		<b>Allotment rate</b>	
		<b>(NT\$)</b>	<b>Amount</b>
Dividends distributed to ordinary shareholders:			
Cash	\$	0.40	50,418
Stock		0.40	50,418
		<b>\$</b>	<b><u>100,836</u></b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

3. Other equity (after tax)

	<b>Exchange difference from translation of the financial statements of foreign operations</b>	<b>Unrealized gains or losses on financial assets at fair value through other comprehensi ve income</b>	<b>Non-controll ing interests</b>	<b>Total</b>
Balance on January 1, 2025	\$ (1,338)	48,342	(20,085)	26,919
Exchange difference from translation of the net assets of foreign operations	528	-	71	599
Unrealized losses on financial assets at fair value through other comprehensive income	-	(37,534)	(2,622)	(40,156)
Balance on March 31, 2025	<u><u>\$ (810)</u></u>	<u><u>10,808</u></u>	<u><u>(22,636)</u></u>	<u><u>(12,638)</u></u>
Balance on January 1, 2024	\$ (2,507)	125,160	(18,494)	104,159
Exchange difference from translation of the net assets of foreign operations	666	-	224	890
Unrealized gains on financial assets at fair value through other comprehensive income	-	52,587	776	53,363
Balance on March 31, 2024	<u><u>\$ (1,841)</u></u>	<u><u>177,747</u></u>	<u><u>(17,494)</u></u>	<u><u>158,412</u></u>

4. Non-controlling interests

	<b>Non-controlli ng interests</b>
Beginning balance on January 1, 2025	\$ 424,171
Net loss for the period attributable to non-controlling interests	(12,894)
Other comprehensive income for the period attributable to non-controlling interests	(2,551)
Capital increase in cash	<u>1,048</u>
Ending balance on March 31, 2025	<u><u>\$ 409,774</u></u>
Beginning balance on January 1, 2024	\$ 467,523
Net loss for the period attributable to non-controlling interests	(11,031)
Other comprehensive income for the period attributable to non-controlling interests	1,001
Changes in ownership interests in subsidiaries	<u>4,899</u>
Ending balance on March 31, 2024	<u><u>\$ 462,392</u></u>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(XXV) Earnings per share

	For the three months ended March 31, 2025	For the three months ended March 31, 2024
<b>Basic earnings per share:</b>		
Net profits attributable to ordinary equity holders of the Company	\$ 31,035	24,529
Weighted average number of outstanding ordinary shares	131,086	131,086
Basic earnings per share (NT\$)	\$ 0.24	0.19
<b>Diluted earnings per share:</b>		
Net profits attributable to ordinary equity holders of the Company for the period (basic)	\$ 31,035	24,529
Effects of dilutive potential ordinary shares		
Net profits attributable to ordinary equity holders of the Company (diluted)	\$ 31,035	24,529
Weighted average number of outstanding ordinary shares (basic)	131,086	131,086
Effects of employee remuneration in stock	543	359
Weighted average number of outstanding ordinary shares (diluted)	131,629	131,445
Diluted earnings per share (NT\$)	\$ 0.24	0.19

(XXVI) Revenue from contracts with customers

1. Disaggregation of revenue

	For the three months ended March 31, 2025			
	Sales of goods	Service provision	Leases	Total
Main regional markets:				
Asia	\$ 855,293	168,283	23,628	1,047,204
Europe	3,813	-	-	3,813
Other countries	561	-	-	561
	<u>\$ 859,667</u>	<u>168,283</u>	<u>23,628</u>	<u>1,051,578</u>
Main product/service lines:				
Medicines and medical materials	\$ 827,720	-	-	827,720
Non-woven filter fabric	31,947	-	-	31,947
Service provision	-	159,291	-	159,291
Equipment leases	-	-	21,216	21,216
Leases of investment properties and properties	-	-	2,412	2,412
Others	-	8,992	-	8,992
	<u>\$ 859,667</u>	<u>168,283</u>	<u>23,628</u>	<u>1,051,578</u>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

<b>For the three months ended March 31, 2024</b>				
	<b>Sales of goods</b>	<b>Service provision</b>	<b>Leases</b>	<b>Total</b>
Main regional markets:				
Asia	\$ 796,093	134,431	39,240	969,764
Europe	2,785	-	-	2,785
	<b>\$ 798,878</b>	<b>134,431</b>	<b>39,240</b>	<b>972,549</b>
Main product/service lines:				
Medicines and medical materials	\$ 768,728	-	-	768,728
Non-woven filter fabric	30,150	-	-	30,150
Service provision	-	134,431	-	134,431
Equipment leases	-	-	23,499	23,499
Leases of investment properties and properties	-	-	15,741	15,741
	<b>\$ 798,878</b>	<b>134,431</b>	<b>39,240</b>	<b>972,549</b>

**2. Contract balance**

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Notes receivable	\$ 8,696	11,320	10,945
Accounts receivable	273,034	263,680	281,814
Accounts receivable - related parties	952,921	972,101	1,030,918
Finance lease receivables	-	-	188
Finance lease receivables - related parties	10,947	11,146	13,046
Long-term finance lease receivables - related parties	14,621	15,969	15,659
Less: loss allowances	(19,993)	(17,628)	(7,701)
	<b>\$ 1,240,226</b>	<b>1,256,588</b>	<b>1,344,869</b>
	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Contract liability - sales of goods	\$ 37,953	47,561	12,898
Contract liability customer loyalty programs	1,672	1,254	1,288
	<b>\$ 39,625</b>	<b>48,815</b>	<b>14,186</b>

## **Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

Please refer to Note 6 (4) and (6) for the disclosure of notes and accounts receivable, as well as financing lease receivables (including related parties) and their impairment.

The beginning balances of contract liabilities on January 1, 2025 and 2024 were recognized for the three months ended March 31, 2025 and 2024 as income of NT\$4,436 thousand and NT\$4,155 thousand, respectively.

### **(XXVII) Employees' and directors' remuneration**

According to the Company's Articles of Incorporation, 6% to 10% of the annual profit (if any) shall be appropriated as remuneration to employees and not more than 3% as remuneration to directors. However, the allowances for the Company's accumulated losses shall be set aside from the profit first. The objects to which the employees' remuneration referred to in the preceding paragraph is paid in stock or cash include employees of affiliated companies who meet certain requirements.

The estimated amounts of employees' remuneration of the Company recognized for the three months ended March 31, 2025 and 2024 were NT\$2,678 thousand and NT\$2,188 thousand, respectively, and the estimated amounts of directors' remuneration were NT\$446 thousand and NT\$365 thousand, respectively. The estimates were based on the Company's net profit before tax in that period less employees' and directors' remuneration, multiplied by the distribution percentages of employees' and directors' remuneration as stipulated in the Company's Articles of Incorporation, and the remuneration was presented in operating expenses for that period. In case of a difference between the actual distribution amount in the following year and the estimated amount recognized, it shall be accounted for as changes in accounting estimates and recognized in profit or loss for the following year.

In 2024 and 2023, the Company appropriated NT\$16,014 thousand and NT\$11,194 thousand respectively for employee remuneration, and NT\$2,669 thousand and NT\$1,866 thousand respectively for directors' remuneration, which did not differ from the resolutions on distribution of employees' and directors' remuneration by the Company's Board of Directors in 2024 and 2023. Relevant information can be found on the MOPS.

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(XXVIII) Other net income and expenses

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Income from sublease of investment property	\$ 10,513	11,447
Gains on disposal of property, plant and equipment	-	136
Lease modification gains	33	-
Income from subleases of right-of-use assets	9,057	9,075
	<b><u>\$ 19,603</u></b>	<b><u>20,658</u></b>

(XXIX) Non-operating income and expenses

1. Interest income

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Bank deposit interest	\$ 1,375	913
Other interest income	150	72
	<b><u>\$ 1,525</u></b>	<b><u>985</u></b>

2. Other income

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Royalty income	\$ 2,241	1,561
Dividend income	1,085	2,445
Government grants	20	-
Logistics income	1,586	1,586
Others	7,495	2,706
	<b><u>\$ 12,427</u></b>	<b><u>8,298</u></b>

3. Other gains and losses

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Foreign exchange gain	\$ 446	1,848
(Losses) gains on financial assets at fair value through profit or loss	(2,566)	4,225
Others	(110)	(121)
	<b><u>\$ (2,230)</u></b>	<b><u>5,952</u></b>



**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

4. Financial cost

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Interest on loans from financial institutions	\$ 9,973	11,186
Amortization of interest on lease liabilities	2,425	2,941
Others	37	-
	<b><u>\$ 12,435</u></b>	<b><u>14,127</u></b>

(XXX) Financial instruments

Except for the following disclosures, there was no significant change in the fair value and exposure to credit risk, liquidity risk, and market risk of financial instrument of the Consolidated Company. For related information, please refer to Note 6 (30) of the Consolidated Financial Statements for the year ended December 31, 2024.

1. Credit risk of accounts receivable

Please refer to Note 6 (4), (5) and (6) for information on the exposure of notes receivable, accounts receivable, finance lease receivables and other receivables to credit risk.

Other financial assets measured at amortized cost include restricted bank deposits, certificates of deposit and refundable deposits.

The restricted bank deposits, time deposits, and refundable deposits held by the Consolidated Company are considered low credit risk as the counterparties and other performing parties are creditworthy or financial institutions rated investment grade or above.

The Consolidated Company made no provision of loss allowances for other financial assets measured at amortized cost as of March 31, 2025, December 31 and March 31, 2024 due to 12-month expected credit losses or lifetime expected credit losses.

2. Liquidity risk

The contractual maturities of financial liabilities are showed in the following table, including the effect of estimated interest.

	<b>Carrying amount</b>	<b>Contractual cash flows</b>	<b>To be paid immediately or within 1 month</b>	<b>Within 6 months</b>	<b>6-12 months</b>	<b>1-3 years</b>	<b>Over 3 years</b>
<b>March 31, 2025</b>							
Non-derivative financial liabilities							
Non-interest bearing liabilities	\$ 816,588	816,588	391,203	411,824	13,561	-	-
lease liabilities	457,925	487,168	9,595	48,642	53,895	159,099	215,937
Floating rate instruments	1,424,379	1,604,051	179,360	218,066	176,321	198,632	831,672
Fixed-rate instruments	34,947	35,000	-	35,000	-	-	-
	<b><u>\$ 2,733,839</u></b>	<b><u>2,942,807</u></b>	<b><u>580,158</u></b>	<b><u>713,532</u></b>	<b><u>243,777</u></b>	<b><u>357,731</u></b>	<b><u>1,047,609</u></b>

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

## December 31, 2024

### Non-derivative financial liabilities

Non-interest bearing liabilities	\$	963,433	963,433	313,778	635,456	14,199	-	-
lease liabilities		488,974	520,525	10,157	51,385	57,477	165,917	235,589
Floating rate instruments		1,443,480	1,506,517	274,429	222,197	153,274	812,092	44,525
Fixed-rate instruments		54,815	55,000	-	55,000	-	-	-
	\$	<b>2,950,702</b>	<b>3,045,475</b>	<b>598,364</b>	<b>964,038</b>	<b>224,950</b>	<b>978,009</b>	<b>280,114</b>

## March 31, 2024

### Non-derivative financial liabilities

Non-interest bearing liabilities	\$	1,022,644	1,022,644	549,908	463,089	1,907	5,820	1,920
lease liabilities		536,945	570,693	10,470	53,069	61,441	198,657	247,056
Floating rate instruments		1,474,894	1,556,336	97,461	218,620	196,324	988,860	55,071
Fixed-rate instruments		54,994	55,000	-	55,000	-	-	-
	\$	<b>3,089,477</b>	<b>3,204,673</b>	<b>657,839</b>	<b>789,778</b>	<b>259,672</b>	<b>1,193,337</b>	<b>304,047</b>

The Combined Company does not expect a significantly earlier occurrence of cash flows based on the due date analysis or significant differences between the actual amounts and estimates.

## 3. Market risk

### (1) Exchange rate risk

The financial assets and liabilities of the Consolidated Company exposed to significant foreign currency exchange rate risk are as follows:

	2025.3.31				2024.12.31			2024.3.31		
	Foreign currency	Exchange rate (NT\$)	NT\$		Foreign currency	Exchange rate (NT\$)	NT\$	Foreign currency	Exchange rate (NT\$)	NT\$
<u>Financial asset</u>										
<u>Monetary items</u>										
USD	\$	1,017	33.205	33,769	1,066	32.79	34,954	1,061	32.00	33,952
CNY		10	4.573	46	10	4.478	45	12	4.408	53
EUR		64	35.97	2,302	101	34.14	3,448	159	34.46	5,479
<u>Non-monetary items</u>										
USD		9,042	33.205	300,240	10,547	32.79	345,783	12,829	32.00	410,528
CNY		5,567	4.573	25,458	5,948	4.478	26,635	6,305	4.408	27,792

The exchange rate risk of the Consolidated Company mainly comes from cash and cash equivalents as well as accounts and borrowings receivable denominated in foreign currencies, which generate foreign currency exchange gains and losses during translation. On March 31, 2025 and 2024, if the NTD appreciated and depreciated by 5% against the USD, RMB and Euro, while all other factors remained unchanged, the

## **Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

net profit before tax for the three months ended March 31, 2025 and 2024 would decrease or increase by NT\$1,806 thousand and NT\$1,974 thousand, respectively. The analysis of the two periods was conducted on the same basis.

Due to the variety of functional currencies used by the Consolidated Company, information on exchange gains and losses on monetary items was disclosed on a consolidated basis. Foreign currency exchange gains (losses) (both realized and unrealized) for the three months ended March 31, 2025 and 2024 amounted to NT\$446 thousand and NT\$1,848 thousand, respectively.

### **(2) Interest rate risk**

The exposure of the Consolidated Company's financial liabilities to interest rate risk is illustrated in Liquidity Risk Management section in this note.

The sensitivity analysis below is based on the exposure of non-derivative instruments to interest rate risk at the reporting date. The analysis of floating rate liabilities is based on the assumption that the outstanding liabilities at the reporting date are outstanding throughout the year. The rate of change in the interest rate reported to major management personnel of the Consolidated Company is the interest rate plus 20 basis points, which also represents the management's evaluation on the reasonably possible range of changes in the interest rate.

If the interest rate increases or decreases by 20 basis points, while all other variables remain unchanged, the pre-tax net profit of the Consolidated Company for the three months ended March 31, 2025 and 2024 will increase or decrease by NT\$2,849 thousand and NT\$2,950 thousand, mainly due to changes in the interest rate of the Consolidated Company's floating rate loans.

## **4. Information on fair value**

### **(1) Types and fair value of financial instruments**

The Consolidated Company's financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured at fair value on a recurring basis. The carrying amounts and fair values of all types of financial assets and financial liabilities (including fair value level information, but for financial instruments not measured at fair value with carrying amounts reasonably approximate to their fair values as well as lease liabilities, fair value information is not required to be disclosed according to the regulations) are listed as follows:

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

2025.3.31					
	Carrying amount	Fair value			
		Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss					
Fund beneficiary certificate	\$ 10,650	10,650	-	-	10,650
Non-TWSE/TPEX listed stocks	25,247	-	-	25,247	25,247
Subtotal	35,897	10,650	-	25,247	35,897
Financial assets at fair value through other comprehensive income					
Non-TWSE/TPEX listed stocks	299,889	-	-	299,889	299,889
Non-overseas listed stocks	300,269	-	-	300,269	300,269
Limited partnership interests	119,948	-	-	119,948	119,948
Subtotal	720,106	-	-	720,106	720,106
Financial assets at amortized cost					
Cash and cash equivalents	1,530,503	-	-	-	-
Restricted bank deposits	93,327	-	-	-	-
Net notes receivable and accounts receivable (including related parties)	1,214,658	-	-	-	-
Other net receivables (including related parties)	58,535	-	-	-	-
Finance lease receivables (including those due within one year)	25,568	-	-	-	-
Subtotal	2,922,591	-	-	-	-
<b>Total</b>	<b>\$ 3,678,594</b>	<b>10,650</b>	<b>-</b>	<b>745,353</b>	<b>756,003</b>
Financial liabilities at amortized cost					
Short-term loans	\$ 446,268	-	-	-	-
Long-term loans (including those due within one year)	978,111	-	-	-	-
Short-term bills payable	34,947	-	-	-	-
Notes and accounts payable (including related parties)	628,089	-	-	-	-
Other payables (including related parties)	188,499	-	-	-	-
Lease liabilities (including those due within one year)	457,925	-	-	-	-
<b>Total</b>	<b>\$ 2,733,839</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

		2024.12.31				
		Carrying amount	Fair value			
			Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss:						
Fund beneficiary certificate	\$	10,610	10,610	-	-	10,610
Non-TWSE/TPEX listed stocks		27,853	-	-	27,853	27,853
Subtotal		38,463	10,610	-	27,853	38,463
Financial assets at fair value through other comprehensive income						
Non-TWSE/TPEX listed stocks		299,873	-	-	299,873	299,873
Non-overseas listed stocks		345,774	-	-	345,774	345,774
Limited partnership interests		125,039	-	-	125,039	125,039
Subtotal		770,686	-	-	770,686	770,686
Financial assets at amortized cost						
Cash and cash equivalents		1,459,635	-	-	-	-
Restricted bank deposits		66,344	-	-	-	-
Net notes receivable and accounts receivable (including related parties)		1,229,473	-	-	-	-
Other net receivables (including related parties)		319,081	-	-	-	-
Finance lease receivables (including those due within one year)		27,115	-	-	-	-
Subtotal		3,101,648	-	-	-	-
Total	\$	3,910,797	10,610	-	798,539	809,149
Financial liabilities at amortized cost						
Short-term loans	\$	433,087	-	-	-	-
Long-term loans (including those due within one year)		1,010,393	-	-	-	-
Short-term bills payable		54,815	-	-	-	-
Notes and accounts payable (including related parties)		685,082	-	-	-	-
Other payables (including related parties)		278,351	-	-	-	-
Lease liabilities (including those due within one year)		488,974	-	-	-	-
Total	\$	2,950,702	-	-	-	-

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

2024.3.31					
	Carrying amount	Fair value			
		Level 1	Level 2	Level 3	Total
Financial assets at fair value through profit or loss:					
Fund beneficiary certificate	\$ 10,497	10,497	-	-	10,497
Non-TWSE/TPEX listed stocks	22,823	-	-	22,823	22,823
Limited partnership interests	25,439	-	-	25,439	25,439
Subtotal	58,759	10,497	-	48,262	58,759
Financial assets at fair value through other comprehensive income					
Non-TWSE/TPEX listed stocks	368,773	-	-	368,773	368,773
Non-overseas listed stocks	410,389	-	-	410,389	410,389
Limited partnership interests	119,062	-	-	119,062	119,062
Subtotal	898,224	-	-	898,224	898,224
2024.3.31					
	Carrying amount	Fair value			
		Level 1	Level 2	Level 3	Total
Financial assets at amortized cost					
Cash and cash equivalents	\$ 1,261,724	-	-	-	-
Restricted bank deposits	93,505	-	-	-	-
Net notes receivable and accounts receivable (including related parties)	1,315,976	-	-	-	-
Other net receivables (including related parties)	89,767	-	-	-	-
Finance lease receivables (including those due within one year)	28,893	-	-	-	-
Subtotal	2,789,865	-	-	-	-
Total	\$ 3,746,848	10,497	-	946,486	956,983
Financial liabilities at amortized cost					
Short-term loans	\$ 367,007	-	-	-	-
Long-term loans (including those due within one year)	1,107,887	-	-	-	-
Short-term bills payable	54,994	-	-	-	-
Notes and accounts payable (including related parties)	798,606	-	-	-	-
Other payables (including related parties)	213,530	-	-	-	-
Long-term accounts payable (including those due within one year)	10,508	-	-	-	-
Lease liabilities (including those due within one year)	536,945	-	-	-	-
Total	\$ 3,089,477	-	-	-	-

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

## (2) Evaluation technology for fair value of financial instruments measured at fair value

If there is a quoted price in an active market for a financial instrument, that price shall be used for measuring fair value. The market prices, announced by the main exchanges and the over-the-counter trading center for central government bonds that are judged to be popular, are the basis for the fair value of listed equity instruments and the debt instruments with a quoted price in an active market. If a quoted price for a financial instrument can be obtained from exchanges, brokers, underwriters, industry associations, pricing service institutions or competent authorities in a timely manner and on a regular basis, and represents actual fair market transactions with sufficient frequency, it is determined that there is a quoted price in an active market for the financial instrument. Where the above conditions are not met, the market is considered inactive. Generally speaking, a large bid-ask spread, a significant increase in bid-ask spread, or a low transaction volume indicates an inactive market.

The fair values of financial instruments held by the Consolidated Company traded in inactive markets are presented below by type and attribute:

- Equity instruments without quoted prices: The fair value is estimated using the market comparable company method and asset method, with the assumptions mainly based on the ratio of the estimated market price to earnings per share of the investee, the earnings multiplier derived from quoted market prices of comparable TWSE/TPEX listed companies, as well as the equity value of net assets. The estimate has adjusted the effect of discount of the equity securities due to lack of market liquidity.

(3) There was no change in the fair value hierarchy of financial assets during the three months ended March 31, 2025 and 2024.

## (4) Statement of Changes in Class III

	Measured at fair value through profit or loss	Measured at fair value through other comprehensive income
	Non-derivative financial assets mandatorily measured at fair value through profit or loss	Equity instruments without publicly quoted prices
January 1, 2025	\$ 27,853	770,686
Total gains or losses		
Recognized in profit or loss	(2,606)	-
Recognized in other comprehensive income	-	(49,692)

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

Capital returned due to capital reduction	-	(888)
March 31, 2025	<b>\$ 25,247</b>	<b>720,106</b>
January 1, 2024	\$ 19,684	814,972
Total gains or losses		
Recognized in profit or loss	4,191	-
Recognized in other comprehensive income	-	66,612
Purchase	24,387	42,510
Disposal	-	(24,387)
Capital returned due to capital reduction	-	(1,483)
March 31, 2024	<b>\$ 48,262</b>	<b>898,224</b>

The above total gains or losses are presented in "other gains and losses" and "unrealized valuation gains (losses) on financial assets measured at fair value through other comprehensive income". Among them, those related to the assets still held on March 31, 2025 and 2024 are as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Total gains or losses		
Recognized in profit or loss (presented in "other gains and losses")	\$ (2,606)	4,191
Recognized in other comprehensive income (presented in "unrealized valuation gains (losses) on financial assets measured at fair value through other comprehensive income")	(49,692)	66,612

(5) Quantitative information on the measurement of the fair value of the unobservable major input value (Class III) in the fair value measurement

The fair values of the Consolidated Company that are categorized into level 3 mainly include financial assets measured at fair value through other comprehensive income - equity securities investments. Most of the fair values of the Consolidated Company categorized into level 3 are with only a single significant unobservable input, except that equity instrument investments without an active market are with multiple significant unobservable inputs. Significant unobservable inputs of equity instrument investments without an active market are independent of each other, without any



# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

correlation among them.

(6) For Class III fair value measurement, sensitivity analysis of fair value to reasonable and possible alternative assumptions

The fair value measurement of financial instruments by the Consolidated Company is reasonable, whereas different valuation models or parameters used for measurement may result in different valuation results. The impact of the changes in evaluation parameters for financial instruments categorized into Level 3 on profits and losses or other comprehensive income for the period is as follows:

	Input value	Upward or downward changes	Changes in fair value reflected in profit or loss		Changes in fair value reflected in other comprehensive income	
			Favorable changes	Adverse changes	Favorable changes	Adverse changes
<b>March 31, 2025</b>						
Financial assets at fair value through profit or loss	Liquidity discount	5%	1,578	(1,578)	-	-
Financial assets at fair value through other comprehensive income	Liquidity discount	5%	-	-	43,165	(42,458)
<b>December 31, 2024</b>						
Financial assets at fair value through profit or loss	Liquidity discount	5%	1,741	(1,741)	-	-
Financial assets at fair value through other comprehensive income	Liquidity discount	5%	-	-	45,954	(45,956)
<b>March 31, 2024</b>						
Financial assets at fair value through profit or loss	Liquidity discount	5%	2,950	(2,471)	-	-
Financial assets at fair value through other comprehensive income	Liquidity discount	5%	-	-	55,107	(55,634)

Favorable and adverse changes for the Consolidated Company refer to fluctuations in fair value, which are calculated by using valuation techniques based on different degrees of unobservable input parameters. For a financial instrument whose fair value is affected by more than one input, the above table only reflects the impact of changes in a single input, and the correlation and variability among the inputs are not taken into account.

## (XXXI) Financial risk management

There was no significant change in objectives and policies of the Consolidated Company's financial risk management and the information disclosed in Note 6 (31) of the Consolidated Financial Statements for the year ended December 31, 2024.

## (XXXII) Capital management

Objectives, policies, and procedures of the Consolidated Company's capital management were consistent with those disclosed in the Consolidated Financial Statements for the year ended December 31, 2024. Also, there were no significant changes in the summarized quantitative information for capital management as disclosed in the Consolidated Financial Statements for the year ended December 31, 2024. Please refer to Note 6 (32) of the Consolidated Financial Statements for the year ended December 31, 2024 for further details.

## (XXXIII) Investing and financing activities in non-cash transactions

The non-cash investing and financing activities of the Consolidated Company during

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

the three months ended March 31, 2025 and 2024 are as follows:

1. Please refer to Note 6 (12) and (13) for obtaining right-of-use assets and investment properties through leasing.

2. Cash paid for purchase of property, plant and equipment is as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Acquisition of property, plant and equipment	\$ 40,597	10,440
Net changes in equipment pre-payments in subsidiaries	326	-
Net changes in equipment payables in subsidiaries	(11,862)	14,259
Cash paid	<b><u>\$ 29,061</u></b>	<b><u>24,699</u></b>

3. Cash paid for purchase of intangible assets is as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Acquisition of intangible assets	\$ 2,192	3,283
Net changes in equipment pre-payments in subsidiaries	(1,540)	-
Net changes in equipment payables in subsidiaries	555	-
Net changes in payables on technology patent authorization	-	168
Cash paid	<b><u>\$ 1,207</u></b>	<b><u>3,451</u></b>

4. Cash received from disposal of property, plant and equipment is as follows:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Disposal of property, plant and equipment	\$ -	333
Loss (gain) on disposal of investment properties	-	(315)
Add: Equipment receivable at beginning of period (recognized as other receivables - related parties)	240,000	-
Cash received	<b><u>\$ 240,000</u></b>	<b><u>18</u></b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

5. The adjustments to liabilities from financing activities are as follows:

			Changes in non-cash items			
			Lease changes	Effects of changes in foreign exchange rates	Others	
	<b>2025.1.1</b>	<b>Cash flows</b>				<b>2025.3.31</b>
Short-term loans	\$ 433,087	13,181	-	-	-	446,268
Short-term bills payable	54,815	(20,000)	-	-	132	34,947
Long-term loans (including those due within one year)	1,010,393	(32,282)	-	-	-	978,111
Lease liabilities (including those due within one year)	488,974	(28,819)	(2,230)	-	-	457,925
Deposits received	19,756	(2,080)	-	-	-	17,676
	<b>\$ 2,007,025</b>	<b>(70,000)</b>	<b>(2,230)</b>	<b>-</b>	<b>132</b>	<b>1,934,927</b>

			Changes in non-cash items			
			Lease changes	Effects of changes in foreign exchange rates	Others	
	<b>2024.1.1</b>	<b>Cash flows</b>				<b>2024.3.31</b>
Short-term loans	\$ 407,467	(30,460)	-	-	-	377,007
Short-term bills payable	54,901	-	-	-	93	54,994
Long-term loans (including those due within one year)	1,126,885	(10,149)	-	-	-	1,116,736
Lease liabilities (including those due within one year)	590,767	(30,631)	209	-	-	560,345
Deposits received	19,606	(803)	-	-	-	18,803
	<b>\$ 2,199,626</b>	<b>(72,043)</b>	<b>209</b>	<b>-</b>	<b>93</b>	<b>2,127,885</b>

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

## VII. Transactions of Related Parties

### (I) Name of and relationship with related parties

The related parties who have traded with the Combined Company during the period covered by the Consolidated Financial Statements are as follows:

Name of the related party	Relationship with the Consolidated Company
Minsheng Medical Holding Co., Ltd.	Parent company
Employee Community Co., Ltd.	Associate
Shangchia Health Business Co., Ltd.	Associate
Air Long-Term Care Co., Ltd.	Associate
Shengyu Health Technologies Co., Ltd.	Associate
Minsheng General Hospital	Substantial related party (Minsheng medical system)
Lungtan Minsheng Hospital	Substantial related party (Minsheng medical system)
Tayuan Minsheng Hospital	Substantial related party (Minsheng medical system)
Home Nursing Center attached to Tayuan Minsheng Hospital	Substantial related party (Minsheng medical system)
YES Chang Sheng Pharmacy	Substantial related party
Minsheng Asset Management Co., Ltd.	Substantial related party
Employee Clinic of Hsinchu Science and Industry Park	Substantial related party
Po'en Management Consulting Co., Ltd.	Substantial related party
Shengli Management Consulting Co., Ltd.	Substantial related party
Pisheng Construction Co., Ltd (hereinafter referred to as Pisheng Construction)	Substantial related party
Zhiyi Clinic	Substantial related party
Shengyu Clinic	Substantial related party
Hafo Clinic	Substantial related party
Fuying Clinic	Substantial related party
Pochih Cultural and Creative Co., Ltd.	Substantial related party
Ssu-Kang Chang	Other related parties
Chin-Shun Huang	Other related parties
Chien-Chiang Chiu	Other related parties
Chang-Ming Hsiao	Other related parties
Ming-Tsung Tsai	Other related parties
Hung-Yi Li	The management
Hung-jen Yang	The management
Kun-chang Yang	The management
Qing-Wen Liu	The management
Ming-Hsun Wu	The management

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(II) Significant transactions with related parties

1. Sales of goods

Category of the related party	Operating revenue	
	For the three months ended March 31, 2025	For the three months ended March 31, 2024
Substantial related party		
Minsheng General Hospital	\$ 265,858	269,331
Others	19,229	19,417
Associate	56	-
Parent company	-	74
	<b>\$ 285,143</b>	<b>288,822</b>

The sales price determined by the Consolidated Company for the above-mentioned related party is the purchase cost plus 5% or more, with the payment term being net 30 to 180 days. Generally, sales are collected in the current month.

2. Service provision

Category of the related party	Service income	
	For the three months ended March 31, 2025	For the three months ended March 31, 2024
Substantial related party		
Minsheng General Hospital	\$ 116,915	77,845
Others	10,578	4,973
Associate	887	1,761
	<b>\$ 128,380</b>	<b>84,579</b>

The service income of the Consolidated Company from the above-mentioned related party mainly comes from undertaking medical examinations and inspections, etc. in cooperation with medical institutions. The two parties has entered into a contract by mutual agreement, with the payment term defined as net 30 to 180 days.

3. Leases

Category of the related party	Lease income	
	For the three months ended March 31, 2025	For the three months ended March 31, 2024
Substantial related party		
Minsheng General Hospital	\$ 14,899	19,982
Fuying Clinic	4,363	11,637
Hafo Clinic	-	2,689
Zhiyi Clinic	872	4,196
Others	916	3,749
	<b>\$ 21,050</b>	<b>42,253</b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

The rent paid by the Consolidated Company to the above-mentioned related party is defined in a lease contract entered into by the two parties by mutual agreement, with the payment term being 30 to 120 days.

4. Accounts receivable - related party

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Substantial related party				
Minsheng General Hospital	Accounts receivable	\$ 832,992	853,467	891,309
Fuying Clinic	Accounts receivable	34,692	40,080	70,183
Others	Accounts receivable	70,666	66,532	67,089
Parent company	Accounts receivable	3	-	-
Substantial related party				
Minsheng General Hospital	Finance lease receivables	3,057	3,307	4,675
Lungtan	Finance lease receivables	1,275	1,508	1,525
Minsheng Hospital				
Tayuan	Finance lease receivables	2,243	2,209	2,110
Minsheng Hospital				
Zhiyi Clinic	Finance lease receivables	2,418	2,482	4,700
Shengyu Clinic	Finance lease receivables	1,446	1,236	-
Others	Finance lease receivables	506	404	37
Substantial related party				
Minsheng General Hospital	Long-term finance lease receivables	607	188	2,296
Lungtan	Long-term finance lease receivables	715	880	1,734
Minsheng Hospital				
Tayuan	Long-term finance lease receivables	4,837	5,411	7,080
Minsheng Hospital				
Shengyu Clinic	Long-term finance lease receivables	5,249	5,562	-
Zhiyi Clinic	Long-term finance lease receivables	365	978	4,549
YES Chang Sheng Pharmacy	Long-term finance lease receivables	2,848	2,950	-
Substantial related party				
Minsheng General Hospital	Other receivables	85	85	170
Tayuan	Other receivables	23	240,000	11
Minsheng Hospital				
Shengyu Clinic	Other receivables	3,684	4,102	-
Hafo Clinic	Other receivables	3,960	3,960	4,337
Fuying Clinic	Other receivables	17,600	17,600	19,088
Others	Other receivables	2,637	2,505	258
		<b>\$ 991,908</b>	<b>1,255,446</b>	<b>1,081,151</b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

5. Payables to related parties

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Substantial related party				
Minsheng General Hospital	Accounts payable	\$ 81	91	105
Fuying Clinic	Accounts payable	751	-	869
Zhiyi Clinic	Accounts payable	-	767	-
Others	Accounts payable	156	162	1,952
Parent company	Other payables	-	-	85
Substantial related party				
Shengyu Clinic	Other payables	336	375	-
Minsheng General Hospital	Other payables	1,026	852	1,461
Fuying Clinic	Other payables	-	15,089	-
Others	Other payables	251	352	216
The management	Other payables	116	10,078	115
Associate	Other payables	179	-	32
		<b>\$ 2,896</b>	<b>27,766</b>	<b>4,835</b>

6. Prepayment

The Consolidated Company's prepayments to related parties are detailed as follows:

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Substantial related party				
Pisheng Construction Associate	Prepayments	\$ 3	935	3,739
Air Long-Term Prepayments Care		-	46	-
		<b>\$ 3</b>	<b>981</b>	<b>3,739</b>

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

7. Endorsement and guarantee

(1) Lease contracts:

<b>Category of the related party</b>	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Substantial related party - Minsheng General Hospital	<u>\$ 229,880</u>	<u>229,880</u>	<u>228,736</u>

(2) Bank loans:

The Consolidated Company's loans from financial institutions are jointly guaranteed by Hung-jen Yang, the Chairperson, from the management team, and Ssu-kang Chang, one of the other related parties.

8. Others

<b>Category of the related party</b>	<b>Account items</b>	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Substantial related party	Operating costs - other expenses	\$ 415	365
Substantial related party	Operating cost - rent expense	220	36
Substantial related party	Operating expenses - other expenses	4,937	3,225
Substantial related party	Operating expenses - rent expense	290	288
Associate	Operating costs - other expenses	117	455
Associate	Operating expenses - other expenses	46	46
Parent company	Operating expenses - rent expense	119	118
Substantial related party	Other income - rental income	667	965
Parent company	Other income and losses - rental income	147	146
Substantial related party	Other income - rental income	7,346	7,276



**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

<b>Category of the related party</b>	<b>Account items</b>	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Substantial related party	Collection on behalf of others	\$ 17	7	22
Substantial related party	Payment on behalf of others	30	55	-
Substantial related party	Temporary payments	95	45	-
Substantial related party				
Minsheng General Hospital	Collection in advance	-	-	57
Shengyu Clinic	Collection in advance	2,476	2,682	-
Associate	Collection in advance	-	132	-
Substantial related party				
Minsheng General Hospital	Refundable deposits	250,050	250,050	250,000
Fuying Clinic	Refundable deposits	57,000	49,000	18,000
Hafo Clinic	Refundable deposits	23,000	23,000	23,000
Zhiyi Clinic	Refundable deposits	56,500	53,900	52,500
Others	Refundable deposits	36,815	36,686	31,686
Parent company	Refundable deposits	83	83	82
Substantial related party				
Minsheng General Hospital	Deposits received	5,850	5,805	5,679
Tayuan Minsheng Hospital	Deposits received	-	902	902
Zhiyi Clinic	Deposits received	3,600	3,600	3,600
Others	Deposits received	-	52	112
Parent company	Deposits received	103	102	102

**Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)**

(III) Transactions with key management personnel

Remuneration paid to key management personnel includes:

	<b>For the three months ended March 31, 2025</b>	<b>For the three months ended March 31, 2024</b>
Short-term employee benefits	\$ 12,265	11,516
Post-employment benefits	300	295
	<b><u>\$ 12,565</u></b>	<b><u>11,811</u></b>

**VIII. Pledged Assets**

The book values of the assets pledged as collateral by the Consolidated Company are as follows:

<b>Name of the asset</b>	<b>Pledge object</b>	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Financial assets at amortized cost - current	Guarantee letters for bank loans and leases	\$ 18,327	23,010	49,005
Financial assets measured at amortized cost - non-current	Guarantees for bank loans and commercial papers	40,000	43,334	44,500
Investment properties	Bank loans	-	-	176,753
Property, plant and equipment	Bank loans	1,116,971	1,121,256	1,134,110
		<b><u>\$ 1,175,298</u></b>	<b><u>1,187,600</u></b>	<b><u>1,404,368</u></b>

**IX. Material Contingent Liabilities and Unrecognized Contractual Commitments**

Material unrecognized contractual commitments

	<b>2025.3.31</b>	<b>2024.12.31</b>	<b>2024.3.31</b>
Purchase of property, plant and equipment	\$ 11,120	12,303	11,073
Construction in progress	-	-	1,490
Purchase of intangible assets	-	-	546
Guaranteed notes issued for bank loan contracts	2,241,000	2,730,000	2,785,500
Issued and unused letters of credit	3,088	3,069	2,010
	<b><u>\$ 2,255,208</u></b>	<b><u>2,745,372</u></b>	<b><u>2,800,619</u></b>

**X. Material Losses from Disasters: none.**

**XI. Material Subsequent Events: none.**

**XII. Others**

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

(I) Employee benefits, and depreciation and amortization expenses are summarized by function as follows:

By function Nature of business	For the three months ended March 31, 2025			For the three months ended March 31, 2024		
	Belonging to operating costs	Belonging to operating expenses	Total	Belonging to operating costs	Belonging to operating expenses	Total
Employee benefit expenses						
Remuneration expenses	35,748	66,525	102,273	29,641	78,044	107,685
Labor and health insurance expenses	3,726	6,944	10,670	2,966	7,567	10,533
Pension expenses	1,786	3,454	5,240	1,544	4,147	5,691
Remuneration to directors	-	1,774	1,774	-	1,570	1,570
Other employee benefit expenses	1,412	3,335	4,747	1,402	3,133	4,535
depreciation expense	31,055	33,529	64,584	41,823	31,449	73,272
Amortization expenses	1,294	4,817	6,111	723	5,565	6,288

(II) Seasonality of operation:

The Consolidated Company's operation of the health examination service is highly seasonal. According to the historical experience, the peak period of the service is around mid-June to before lunar new year of the next year. Therefore, large amount of sales will be recognized when services are actually performed every year from mid-June to next year before lunar new year.

## XIII. Items Disclosed in Notes

(I) Information on major transactions

The information on major transactions that the Consolidated Company should disclose in accordance with the Regulations Governing the Preparation of Financial Statements by Securities Issuers during the three months ended March 31, 2025 is as follows:

1. Lending of funds to others: None.
2. Making of endorsements and guarantees for others:

Unit: NT\$ thousand

No.	Name of the endorser /guarantor	Endorsed /guaranteed party		Limit of endorsement /guarantee amount for a single enterprise	Maximum endorsement /guarantee balance for the period	Ending endorsement /guarantee balance	Actual drawdown amount	Amount of property pledged for Endorsements /guarantees	Ratio of accumulated Endorsements /guarantees to net value in the latest financial statements	Maximum amount for Endorsements /guarantees	Endorsements /guarantees provided by parent company to subsidiaries	Endorsements /guarantees provided by subsidiaries to parent company	Endorsements /guarantees in China
		Name of company	Relationship										
0	ShareHope Medicine Co., Ltd.	Minsheng General Hospital	1	1,590,480	229,880	229,880	229,880	-	6.47%	1,775,462	N	N	N

Note 1: The explanation of the number column is as follows:

- (1) Fill in 0 for the issuer.
- (2) The investees are numbered sequentially with Arabic numerals starting from 1 by company type.

## Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

Note 2: There are 7 types of relationships between the endorser and the endorsee. Please mark the type:

- (1) Companies with who the Company does business.
- (2) Companies in which the Company directly and indirectly holds more than 50% of the voting shares.
- (3) Companies that directly and indirectly hold more than 50% of the Company's voting shares.
- (4) Companies in which the Company directly and indirectly holds more than 90% of the voting shares.
- (5) Companies among the peers and co-contractors that provide mutual guarantee for the purposes of undertaking projects in accordance with contractual terms.
- (6) Companies that are endorsed /guaranteed by all contributing shareholders in proportion to their shareholdings due to joint investments.
- (7) Peers who provide joint guarantees for the performance of house presales contracts in accordance with the Consumer Protection Act.

Note 3: The limits specified in the Procedures for Endorsement and Guarantee of ShareHope Medicine Co., Ltd. are as follows:

- (1) The endorsement and guarantee amount for a single enterprise shall not exceed 20% of the current net value, and the amount of an endorsement /guarantee provided for a transaction shall not exceed the total amount of the transaction made by the enterprise with ShareHope Medicine Co., Ltd.
- (2) The total amount of endorsements and guarantees provided for others shall not exceed 50% of the current net value.

### 3. Material securities held at the end of the period (excluding investments in subsidiaries and affiliates, and interests in joint ventures):

Unit: NT\$ thousand

Holder of securities	Type and name of securities	Relationship with securities issuer	Accounting subject	End of period				Remarks
				Contribution amount/ number of shares (thousand shares or units)	Carrying amount	Shareholding ratio	Fair value	
The Company	Fund beneficiary certificate Union Money Market Fund	None	Financial assets at fair value through profit or loss - current	771	10,650	-	10,650	
The Company	Stock Tsaishin Health Business Co., Ltd.	None	Financial assets at fair value through profit or loss - non-current	1,000	25,247	3.70 %	25,247	
The Company	Stock Yichuang Second Venture Capital Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	2,000	16,914	0.92 %	16,914	
The Company	Stock Chunghua Development Biomedical Venture Capital Co., Ltd.	The Company is a legal representative supervisor of the company	Financial assets at fair value through other comprehensive income - non-current	4,311	29,201	2.86 %	29,201	
The Company	Stock Yiting Biotech Venture Capital Co., Ltd.	The Company is a legal person director of the company	Financial assets at fair value through other comprehensive income - non-current	4,095	41,798	7.50 %	41,798	
The Company	Stock BenQ BM Holding Cayman Corporation	None	Financial assets at fair value through other comprehensive income - non-current	5,258	300,269	2.15 %	300,269	
The Company	Chunghua Development Second Biomedical Venture Capital Limited Partnership	None	Financial assets at fair value through other comprehensive income - non-current	86,346	96,568	3.22 %	96,568	
The Company	Stock-AcroViz Inc.	None	Financial assets at fair value through other comprehensive income - non-current	1,820	26,772	8.88 %	26,772	
The Company	Stock-UltraE Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,176	20,691	6.47 %	20,691	
The Company	Stock - Yaosheng Information Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	500	28,161	10.00 %	28,161	
Mytrex Health Company	Stock-Minsheng Asset Management Co., Ltd.	The chairperson of the Company is a director of the company	Financial assets at fair value through other comprehensive income - non-current	2,120	20,599	3.37 %	20,599	
Mytrex Health Company	Stock Shangching Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income -	68	1,620	0.81 %	1,620	

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

Holder of securities	Type and name of securities	Relationship with securities issuer	Accounting subject	End of period				Remarks
				Contribution amount/ number of shares (thousand shares or units)	Carrying amount	Shareholding ratio	Fair value	
Mytrex Health Company	Stock Intelligent Medical Technology Co., Ltd.	None	non-current Financial assets at fair value through other comprehensive income - non-current	1,760	32,920	9.99 %	32,920	
Mytrex Health Company	Stock Yiho Smart Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	250	7,625	19.53 %	7,625	
Mytrex Health Company	Stock Yichuang Second Venture Capital Co., Ltd.	The Company is a director of the company	Financial assets at fair value through other comprehensive income - non-current	5,000	42,286	2.29 %	42,286	
Pregetic Health Company	Stock Yita International Hospital Management Consulting Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	417	4,637	4.20 %	4,637	
Pregetic Health Company	Stock Juichuan Data Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,000	11,771	8.70 %	11,771	
Pregetic Health Company	Stock Kangchien Gene Technology Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	1,304	11,951	14.81 %	11,951	
Hung-Han Company	Stock Juichuan Data Co., Ltd.	None	Financial assets at fair value through other comprehensive income - non-current	250	2,943	2.17 %	2,943	
Macro Global Corporation	Limited partnership equity Chunchuang Development Venture Capital Limited Partnership	None	Financial assets at fair value through other comprehensive income - non-current	18,164	23,380	1.75 %	23,380	
					720,106		720,106	

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

4. The amounts from purchase and sale of goods from and to related parties that amount to NT\$100 million or account for more than 20% of the paid-in capital:

Unit: NT\$ thousand

Purchaser (seller)	Name of the counterparty	Relationship	Transaction details				Cases where transactions are made in different conditions from general transactions and the reasons		Notes and accounts receivable (payable)		Remarks
			Purchase (sell)	amount	Ratio of the amount to total purchases (sales)	Credit period	Unit price	Credit period	Balance	Ratio of the balance to notes and accounts receivable (payable)	
The Company	Minsheng General Hospital	Substantial related party	(Sell)	(265,710)	(46.52) %	Net 180 days	-		594,225	57.58%	
The Company	Minsheng General Hospital	Substantial related party	Service income	(108,222)	(18.95) %	Net 30-180 days	-		226,988	21.99%	
The Company	Minsheng General Hospital	Substantial related party	Lease income	(14,690)	(2.57) %	Net 30-180 days	-		8,914	0.86%	
									<b>830,127</b>		
The Company	YES Health Company	Subsidiary	(Sell)	(53,740)	(9.41) %	Net 60 days	-		56,428	5.47%	Note
YES Health Company	The Company	Parent company	Purchase	53,740	14.65 %	Net 60 days	-		(56,428)	(28.58)%	Note

Note: This transaction has been written off in the preparation of the Consolidated financial statements.

5. Receivables from related parties amount to NT\$100 million or account for more than 20% of the paid-in capital:

Unit: NT\$ thousand

Payee of the accounts receivable	Name of the counterparty	Relationship	Balance of related party receivables	Turnover rate	Overdue related party receivables		Amount received in subsequent periods	Provision for loss allowances
					amount	Accounting treatment		
The Company	Minsheng General Hospital	Substantial related party	830,127	1.86	-		149,561	-

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

6. Business relationship and major transactions between the parent company and the subsidiaries:

Unit: NT\$ thousand

No.	Name of trading party	Counterparty	Relationship with counterparty	Transaction situation			
				Item	amount	Transaction condition	Ratio of the amount to consolidated total operating income or total assets
0	The Company	YES Health Company	1	Sales income	53,740	Net 60 days	5.11%
0	"	"	1	Accounts receivable - related parties	56,428	"	0.82%

Note 1. The rules for filling in the serial numbers are as follows:

1. 0 represents the parent company.

Note 2. The types of relationship with counterparties are listed as follows:

1. Parent to subsidiary.

2. Subsidiary to parent.

3. Subsidiary to subsidiary.

Note 3. For the business relationship and major transactions between parent and subsidiaries, only information on sales and receivables is disclosed, and the corresponding purchases and payables will not be presented.

Note 4. The above transactions have been written off in the preparation of the Consolidated Financial Statements.

(II) Information on reinvestment (excluding investees in mainland China):

Information on reinvestment business of the Consolidated Company for the three months ended March 31, 2025 were as follows:

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

Unit: NT\$ thousand/thousand shares

Name of investee	Name of investee	Region	Principal business	Initial investment amount		Shareholding at the end of the period			Profits and losses of the investee for the period	Investment income and losses recognized for the period	Remarks
				End of the period	End of last year	Number of shares	Ratio	Carrying amount			
The Company	Mytrex Health Company	Taoyuan City	Manufacturing and processing of non-woven fabrics and sales of medical and sanitary materials	310,286	310,286	22,454	61.46%	355,296	(2,383)	(1,465)	Note 1
The Company	ShareHope Hong Kong Company	Hong Kong, China	Investment management	44,831	44,831	1,500	100.00%	19,412	(1,208)	(1,208)	Note 1
The Company	Chungyuan Medical Management Company	Taoyuan City	Management Consulting Services	11,389	11,389	1,000	100.00%	11,691	23	23	Note 1
The Company	Medzoneasia	Taoyuan City	Health management services and hotels	-	338,169	-	- %	-	-	-	Note 4
The Company	Pregetic Health Company	Taoyuan City	Health management services	122,006	122,006	12,601	38.19%	70,988	(17,389)	(6,641)	Note 1
The Company	Shengshih Technology Co., Ltd.	Taipei City	Management Consulting Services	1,000	1,000	100	100.00%	670	(19)	(19)	Note 1
The Company	Digimed	Taipei City	Information software services	6,000	-	600	60.00%	2,055	(431)	(259)	Note 1 and 3
The Company	TECHGROUP	New Taipei City	Medical information software services	50,759	-	1	51.00%	36,717	208	(629)	Note 1 and 3
The Company	Global Biotech Multimedia Co., Ltd.	Taipei City	Magazine (periodical) publication	10,000	-	500	23.98%	9,681	1,159	318	Note 2 and 3
The Company	Shengyu Health Technologies Co., Ltd.	Taoyuan City	Other management consulting services	2,000	-	200	40.00%	-	-	-	Note 2 and 3
Medzoneasia	Digimed	Taipei City	Information software services	-	6,000	-	- %	-	-	-	Note 1 and 3
Medzoneasia	TECHGROUP	New Taipei City	Medical information software services	-	50,759	-	- %	-	-	-	Note 1 and 3
Medzoneasia	Global Biotech Multimedia Co., Ltd.	Taipei City	Magazine (periodical) publication	-	10,000	-	- %	-	-	-	Note 2 and 3
Medzoneasia	Shengyu Health Technologies Co., Ltd.	Taoyuan City	Other management consulting services	-	2,000	-	- %	-	-	-	Note 2 and 3
Mytrex Health Company	Mytrex USA Co.	California, USA	Health care support services	23,516	23,516	800	88.89%	13,066	(132)	(117)	Note 1
Mytrex Health Company	Air Long-Term Care Co., Ltd.	Taoyuan City	Management Consulting Services	10,000	10,000	667	22.37%	11,090	578	129	Note 2
Mytrex Health Company	Mytrex	Taoyuan City	Manufacturing and processing of non-woven fabrics and sales of medical and sanitary materials	447,888	447,888	6,000	100.00%	61,134	1,134	1,105	Note 1
Mytrex Health Company	Sheng Yo Company	Tainan City	Health management services	23,333	22,381	4,381	47.62%	7,302	(998)	(475)	Note 1
Mytrex Health Company	YES Health Company	Taoyuan City	Wholesale and trading of medicines and management consulting for pharmacies	230,000	230,000	6,035	100.00%	207,431	4	(159)	Note 1
Chungyuan Medical Management Company	Air Long-Term Care Co., Ltd.	Taoyuan City	Management Consulting Services	2,000	2,000	200	6.71%	2,274	578	39	Note 2
Pregetic Health Company	Hung-Han Company	Taipei City	Health management services	128,880	128,880	3,420	100.00%	57,999	46	(252)	Note 1
Pregetic Health Company	Employee Community Co., Ltd.	Taipei City	Advertising	1,700	1,700	170	48.57%	356	(342)	(637)	Note 2
Pregetic Health Company	Harvard Company	Taipei City	Health management consulting services	259,288	259,288	12,000	100.00%	156,982	(8,024)	(8,158)	Note 1
Pregetic Health Company	Anchun Technology Co., Ltd.	Taipei City	Health management services	20,000	20,000	2,000	40.00%	14,562	(1,278)	(511)	Note 2
Pregetic Health Company	Shangchia Health Business Co., Ltd.	Taipei City	Health management services	36,527	36,527	3,390	30.82%	37,064	(474)	(367)	Note 2
Hung-Han Company	Macro Global Corporation	Taichung City	Wholesale and trading of medicines	74,970	74,970	6,460	100.00%	77,353	1,497	1,497	Note 1
YES Health Company	Digimed	Taipei City	Information software services	2,000	2,000	200	20.00%	685	(431)	(86)	Note 1

Note 1: It is a subsidiary, and this transaction has been written off in the preparation of the Consolidated



# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

financial statements.

Note 2: It is an affiliate of the Company.

Note 3: In response to the reorganization of the Group, the investee, Medzoneasia, was merged by the parent company in January 2025. Therefore, the investee was directly held by the Company.

Note 4: The Company and Medzoneasia conducted a short-form merger in January 2025. After the merger, the Company is the surviving company and Medzoneasia is discontinued.

## (III) Information on investments in mainland China:

### 1. Information on reinvestments in mainland China:

Unit: NT\$/US\$ thousand

Name of investee company in Mainland China	Principal business	Paid-in capital	Investment method (Note 1)	Accumulated investment amount remitted from Taiwan at the beginning of the period	Investment amount remitted outward or inward in the period		Accumulated investment amount remitted from Taiwan at the end of the period	Profits and losses of the investee for the period	Shareholding ratio of the Company's direct or indirect investment	Investment income and losses recognized for the period (Note 2)	Book value of investment at the end of the period	Investment income repatriated as of the end of the period
					Outward remittance	Inward remittance						
Minsheng (Tianjin) Investment Management Co., Ltd.	Investment management	11,885	(II)	11,885	-	-	11,885	(835)	100.00%	(835)	1,316	-
Minsheng Asia-Pacific (Beijing) Enterprise Management Co., Ltd.	Hospital management consulting services	5,124	(I)	5,124	-	-	5,124	(511)	100.00%	(511)	6,044	-

Note 1: Investment methods can be classified into the following three types:

(I) Directly invest in mainland China.

(II) Reinvest in mainland companies through third regions.

(III) Other methods.

Note 2: Financial statements reviewed by a certified public accountant of the parent company in Taiwan.

Note 3: The above transactions have been written off in the preparation of the Consolidated Financial Statements.

### 2. Limits for reinvestment in mainland China:

Unit: NT\$ thousand

Accumulated investment amount remitted from Taiwan to mainland China as of the end of the period	Investment amount approved by the Investment Commission of the Ministry of Economic Affairs	Mainland China investment limit stipulated by the Investment Commission of the Ministry of Economic Affairs (Note)
17,009	17,009	2,130,554

Note: 60% of the net value.

### 3. Information on major transactions: None.

# Notes to the Consolidated Financial Statements of ShareHope Medicine Co., Ltd. and its subsidiaries (Continued)

## XIV. Department Information

For the three months ended March 31, 2025							
	Pharmaceu tical Distributio n Departmen t	Health Managem ent Departme nt	Technolo gical Materials Departme nt	Hospital Departme nt	Other departme nts	Adjustme nt and cancellati on	Total
Income:							
Revenue from external customers	\$ 787,585	118,602	31,947	53,913	59,531	-	1,051,578
Interdepartmental revenue	54,418	1,385	-	-	625	(56,428)	-
Total revenue	<u>\$ 842,003</u>	<u>119,987</u>	<u>31,947</u>	<u>53,913</u>	<u>60,156</u>	<u>(56,428)</u>	<u>1,051,578</u>
Profits and losses of reportable departments	<u>\$ 20,911</u>	<u>5,582</u>	<u>3,933</u>	<u>48,333</u>	<u>(59,345)</u>	<u>9,353</u>	<u>28,767</u>

For the three months ended March 31, 2024							
	Pharmaceu tical Distributio n Departmen t	Health Managem ent Departme nt	Technolo gical Materials Departme nt	Hospital Departme nt	Other departme nts	Adjustme nt and cancellati on	Total
Income:							
Revenue from external customers	\$ 710,845	147,880	30,150	14,524	69,150	-	972,549
Interdepartmental revenue	48,275	2,080	-	-	6,204	(56,559)	-
Total revenue	<u>\$ 759,120</u>	<u>149,960</u>	<u>30,150</u>	<u>14,524</u>	<u>75,354</u>	<u>(56,559)</u>	<u>972,549</u>
Profits and losses of reportable departments	<u>\$ 20,610</u>	<u>19,549</u>	<u>3,285</u>	<u>9,495</u>	<u>(46,725)</u>	<u>18,170</u>	<u>24,384</u>